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whereby the mutation was in gpr124, an established gene important for BBB development in mammals.
The gpr124 mutant validates that we were able to find genetic modifiers of BBB development in our
forward genetic screen. The execution of these screens will not only advance our understanding of BBB
development but potentially reveal novel genes and molecules that could be targeted for CNS drug
delivery.
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ABSTRACT
The blood-brain barrier (BBB) maintains a homeostatic environment as well as
prohibits the entrance of xenobiotics into the brain. Because of these qualities, drug
delivery is a fundamental challenge for the treatment of many diseases of the central
nervous system (CNS). Along with limiting the access of therapeutics into the brain, the
BBB is also impaired in CNS pathologies. Understanding the molecular cues that are
essential for healthy BBB development and integrity may reveal targets for drug delivery
leading to decreased progression or possible treatment of many detrimental CNS
diseases. While the central features of the BBB have been accepted, an innovative model
has yet to creatively utilize this established knowledge to decipher how the unique signals
controlling BBB properties can be optimally targeted. To overcome these scientific
barriers, we used zebrafish as a model organism to study BBB development in vivo. We
hypothesized that zebrafish could be used to genetically dissect the molecular
mechanisms important for the development, function, and maintenance of the BBB. The
ultimate goal of this project was to use the zebrafish model for unbiased genetic and
small molecule screens. To fulfill these goals, we produced a BBB reporter line,
Tg(glut1b:mCherry)sj1, to characterize the in vivo development of the BBB. We were
able to show through live imaging and proof-of-principle experiments, that the processes
of CNS angiogenesis and barriergenesis occur concurrently, but do so via independent
mechanisms. We then initiated a forward genetic and small molecule screen with our
BBB reporter line. From these unbiased, high-throughput approaches, we uncovered
several BBB mutants and chemical hits that modulate CNS angiogenesis and the glut1b
promoter. We also cloned one of these genetic mutants whereby the mutation was in
gpr124, an established gene important for BBB development in mammals. The gpr124
mutant validates that we were able to find genetic modifiers of BBB development in our
forward genetic screen. The execution of these screens will not only advance our
understanding of BBB development but potentially reveal novel genes and molecules that
could be targeted for CNS drug delivery.
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CHAPTER 1.

INTRODUCTION*

Background of the Blood-Brain Barrier
The blood-brain barrier (BBB) is a unique structure crucial for maintaining
central nervous system (CNS) homeostasis. The physical and chemical properties of
brain endothelial cells (BECs) regulate the access of compounds from blood to brain and
brain to blood. While it is necessary for BECs to retain these properties, this
physiological system hinders the efficacious delivery of therapeutics into the CNS. Even
though the BBB was discovered over a century ago, molecular mechanisms and
interacting cell types necessary for BBB function and integrity have only recently
become uncovered. The field of BBB biology could benefit from innovatively utilizing a
model system to dissect elements crucial for barrier properties. These molecular
pathways could be modulated to aid in drug delivery and prevent disease progression.
Blood-Brain Barrier in Health and Disease
The BBB is one of three blood-CNS barriers playing a major role in CNS health
and disease. The BBB is endothelial cell based unlike the epithelial cell based choroid
plexus and arachnoid barriers that exist between the cerebral spinal fluid (CSF) and
blood1. Each of these barriers exhibits a unique physical and molecular signature in order
to protect the CNS. While all three barriers contribute to a healthy CNS, studies on the
BBB have been more prominent in the past few decades.
A healthy neurovascular structure is necessary for neuronal function as the brain
is a highly metabolic organ, requiring 20% of cardiac output2. The BBB maintains the
proper environment crucial for neuronal activity, ionic homeostasis, and prohibits
harmful xenobiotics from entering the brain parenchyma2. These functions provide the
brain with a chemical safeguard and prevent neural complications. However, it is
unknown whether alteration of the BBB is a cause or effect of disease states. The BBB is
disrupted in many CNS pathologies such as Alzheimer’s disease, Parkinson’s disease,
Multiple Sclerosis, AIDS Dementia, stroke, and epilepsy2,3. Reduction in blood flow in
the aging brain may lead to a change in cerebral protein synthesis, action potential firing,
and electrolyte dysbalance2. In a recent study by Bell et al. (2010), it was suggested that
BBB break down exists before disease progression4. Their mouse model of pericyte loss
in the adult brain produced vascular defects and the subsequent initiation of secondary
neurodegenerative changes4. The health and function of the BBB not only plays a role in
the pathophysiology of CNS disease, but also in the treatment of conditions such as CNS
tumors.
*Modified with permission. Umans, R. A. & Taylor, M. R. Zebrafish as a model to study
drug transporters at the blood-brain barrier. Clin Pharmacol Ther 92, 567-570,
doi:10.1038/clpt.2012.168 (2012).
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Drug Delivery Across the Blood-Brain Barrier
The protection the BBB offers the brain simultaneously prohibits the access of
most therapeutics from entering the CNS. In fact, around 100% of large molecules and
98% of small molecules are excluded from entering the brain5. CNS drug penetration is
dependent on drug lipid solubility as well as a lower molecular weight6. These
therapeutic limitations are imposed by a lack of fenestrations, presence of tight junctions,
and expression of multi-drug resistance efflux pumps on BECs7. The main multi-drug
resistance protein found in the BBB, P-glycoprotein, was discovered due to its overexpression in cancer cells and consequently was found to be one of the major players for
drug resistance at the BBB8,9. P-glycoprotein, as well as other members of the multi-drug
resistance protein families, excludes various anti-cancer, anti-psychotic, anti-epileptic,
and anti-HIV drugs7. While it is necessary for the BBB to regulate the passage of
compounds into the brain, this access is not biased towards compounds that could
otherwise medicate CNS diseases.
To more effectively deliver therapeutics into the CNS, various approaches and
targets have been established. Biomedical and chemical tactics are commonly employed
to more effectively deliver drugs into the CNS. Receptor-mediated endocytosis of
biodegradable nanoparticles coated in various drugs successfully traverse the barrier in
vitro and in vivo10. Multi-drug resistance transporters and other endogenous mechanisms
may be targeted for CNS drug delivery although a good structure-activity relationship is
needed for effective drug design. Drugs can be designed as transporter substrates or
conversely inhibit transporters to allow more uptake of the desired therapeutic11,12. Aside
from biochemical approaches, physical techniques have also been investigated for
opening up the BBB. MRI- targeted ultrasound has been shown to breakdown the
paracellular barrier between BECs in a focused area13. MRI-induced BBB opening
allowed the delivery of antibodies in the CNS yet physical damage to tissue is an artifact
of this process14. More invasive methods exist, such as intra-cerebro-infusion and
biodegradable implants aiming to physically break down the barrier and locally deliver
therapy15. However, it is less likely patients would prefer a more crude, surgical
technique, especially since drugs diffuse better into the blood versus the brain and
multiple implants may need to be transplanted in order to have an effective treatment
volume6,16. Drug delivery through the olfactory system is also a route for CNS drug
delivery. Molecules move into the brain through the nose by entering the olfactory CSF,
very similarly to intra-cerebro-infusions, yet less invasive16. Several kinds of compounds
such as sulfonamides, insulin, and progesterone have entered the CNS via nasal delivery
but measures need to be taken as to not allow viruses or bacteria to enter the CNS
through this course11.
Blood-Brain Barrier Structure
The BBB was first described over a century ago by Paul Ehrlich as he injected
various water-soluble dyes into circulation and witnessed their exclusion from the brain
and spinal cord17,18. Edwin Goldmann, Ehrlich’s student, further characterized these

2

observations through which he witnessed the retention of trypan blue in the CSF and not
the periphery when injected directly into the CSF19. The term “blood-brain barrier” was
however created by Max Lewandowksy whereby he discovered neurotoxic agents only
had a harmful effect after direct injection into the brain20. These pioneering experiments
laid the ground work for the presence of a functional barrier but still posed the question
of how and why it developed. In fact, it wasn’t until 1969 that Brightman and Reese first
localized tight junction proteins in between BECs, identifying the structure that was
responsible for controlling passive diffusion of different molecules21.
Since then, it has been widely established that the selectivity of the barrier is due
in part to both its physical and chemical barriers2. Tight junctions, proteins anchored
between endothelial cells, are important for establishing the paracellular regulation
between cells. The main classes of tight junction proteins are Occludins and Claudins,
tethered between cells by junction adhesion molecules. When absent, loss of Claudin5
causes a size-selective loosening of the BBB22. In addition to a physical blockade, these
proteins mediate the restriction of small molecule movement through trans-endothelial
electrical resistance (TEER). In fact, TEER in the periphery is reported to be fifty times
lower than between BECs23. Transporters, both carrier mediated and active efflux,
regulate the access of particular nutrients as well as prohibit the entry of xenobiotics into
the brain2. Throughout the CNS, transporters traffic a diverse range of compounds.
Several classes of transporters exist along blood-CNS barriers to direct the proper
distribution of drugs, xenobiotics, and nutrients.
While different transporters are isolated to specific locations among the bloodCNS barriers, transporters of the BBB are perhaps the best characterized. With over 40
individual members of the ATP-binding cassette (ABC) family, ABC transporters are the
most widely studied drug transporters at the BBB. Of the ABC transporters, ABCB1,
also known as Multidrug Resistance Protein 1 (MDR1) and P-glycoprotein, plays a
prominent function in excluding compounds from the CNS. Other ABC family members
such as BCRP (ABCG2) and MRP4 (ABCC4) are also highly expressed at the BBB and
play important roles in drug transport7. Knockout mice of the MDR1 mouse ortholog,
Mdr1a, revealed higher sensitivities to both neurotoxic Ivermectin and chemotherapeutic
Vinblastine compared to wild-type littermates, indicating a protective activity of MDR1a
at the mouse BBB24. Since its discovery, many groups have attempted to modulate
MDR1 function as a means to alter therapeutic bioavailability and to overcome multidrug
resistance.
In addition to drug efflux transporters, BECs express many anionic and carrier
mediated systems to deliver the proper nutrition to the CNS. Organic anion transporters
mediate the distribution of neurotransmitter (NT) metabolites as well as other anions
throughout the CNS25. Amino acid transporters help deliver essential amino acids as well
as regulate potential amino acid neurotoxicity in the CNS2. Glucose Transporter 1
(GLUT1), a solute carrier, is vital for proper brain function since glucose is impermeant
to the BBB and the brain uses approximately 20% of whole-body glucose26. GLUT1 is
highly expressed in BECs in order to provide energy to the brain and is often used as a
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marker for BBB localization and function27. GLUT1 is also one of the earliest BBB
markers as it is expressed in BECs early in brain development28.
Furthermore, it is still widely debated in the field of brain barrier biology whether
angiogenesis and barriergenesis occur simultaneously or in a two-step process1. The first
hypothesis suggests that barriergenesis occurs as soon as angiogenesis takes place in the
brain. The second hypothesis suggests that angiogenesis of leaky, immature vessels
occurs in the brain followed later by barriergenesis whereby BECs adapt the BBB
phenotype. In order to advance the field of BBB biology and answer these unsettled
mysteries about barriergenesis, innovative strategies must be applied to study BBB
development in vivo and find novel signals controlling this process.
In addition to the structural components of the BBB, different cell types associate
with BECs to fully establish what is deemed the neurovascular unit (NVU)
(Figure 1-1)23. The NVU is a physiological arrangement of BECs, neurons, astrocytes,
pericytes, and microglia2. Pericytes, a kind of smooth muscle cell, develop during initial
CNS angiogenesis in the rat at E12 and E11.5 in mouse before astrocytic endfeet
ensheath BECs post-natally27 29 1. Initially, astrocytes were speculated to be the cell type
important for barriergenesis as astrocytes relay cell non-autonomous signals important for
barrier differentiation and function30. It is now understood that pericytes are important
for barrier function in mice at a time when astrocytes have not yet developed27.
Microglia, the primary immune cell of the CNS, survey their environment and change
into phagocytic cells when activated2. Many studies are now aimed at deciphering the
molecular cues that ensue between the cell types of the NVU as a means to target them
therapeutically.
Molecular Mechanisms that Regulate the Blood-Brain Barrier
The signals important for BBB development are still not completely understood.
Although much remains unknown about signaling during BBB development, certain
pathways and molecules essential for barriergenesis have recently been uncovered. The
cell types of the NVU relay cell-autonomous and non-autonomous signals to one another
in order to create a functional BBB31 32 33 34,35. Daneman et al. (2009) demonstrated that
Wnt signaling is important for CNS angiogenesis but not peripheral angiogenesis,
suggesting that Wnt is included in a distinct signaling profile for BBB development36. GCoupled Protein Receptor 124 (GPR124), an orphan g-coupled protein receptor upregulated in colorectal cancer, is also crucial for proper BBB formation34,35.
Interestingly, both Wnt and GPR124 mutant mice have similar phenotypes, including
embryonic lethality and abnormal CNS angiogenesis in the forebrain and spinal cord35,36.
Additionally, Sonic hedgehog (Shh) has been suggested to promote barrier integrity
through secretion of Shh by astrocytes33. These findings advance the understanding of
signals important in BBB development, but do so using a candidate gene approach.
While effective, such methods may shed bias on results, especially since some of these
pathways are already established to be important for brain development37,38.
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Figure 1-1. The neurovascular unit illustrating the various cell types of the bloodbrain barrier
Brain endothelial cells interact with pericytes, astrocytes, neurons and microglia to
maintain CNS homeostasis.
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In recent years, the molecular signatures of BECs have been investigated in order
to find specific targets at the BBB. Daneman et al. (2010) compared the transcriptional
profile of isolated BECs compared to vessels found in the liver and lung39. From this
study, a mouse BBB transcriptome was developed as a resource for further understanding
what signals are enriched in this brain barrier. Ben-Zvi et al. (2014) recapitulated a
similar assay, isolating Mfsd2a as a BBB enriched gene40. Knockout of Mfsd2a resulted
in normal vascular patterning but a leakier BBB40. Genes such as Mfsd2a and ones found
in the mouse BBB transcriptome could ideally be targeted for CNS drug delivery.
Models Used to Study the Blood-Brain Barrier
Different Models to Study the Blood-Brain Barrier
A variety of models are used to study BBB function and its molecular
mechanisms. Just as Ehrlich used several animal models to assess BBB function over a
century ago, a current array of models exists to study BBB development and maturation.
Among the models used are avian, rodent, insect, and tissue culture systems. Avian
studies first suggested there are signals in the brain milieu responsible for BBB
development32. Stewart and Wiley (1981) performed transplantation studies revealing
peripheral vessels could adopt BBB features when they vascularized CNS transplanted
tissue, suggesting a difference between the microenvironment of the periphery of the
body and the brain32. Rodent models, which are most popularly used, have helped
identify the proteins important to the physical and chemical barriers of the BBB, the cell
types that are important in the NVU, the consequences of particular cell type loss, the
expression patterns of BBB markers, and signals that are communicated between these
cell types21,24,27,28,30,31,33-36,39-41. Armulik et al. (2010) demonstrated that pericytes in the
rodent BBB are crucial for proper regulation by maintaining BBB function, BBB-specific
gene expression, and astrocytic end-feet contact41. This significant finding also
contradicted previous theories that suggested that astrocytes regulate BBB formation
even though pericytes develop before astrocytes1,30. Furthermore, insect models possess
technical advantages as they are used easily and rapidly in molecular biology42. Mayer et
al. (2009) demonstrated an evolutionary conservation of the BBB in Drosophila
melanogaster and further demonstrated the use of fruit flies for studying BBB
physiology43. Tissue culture systems are utilized independently or in combination with
rodent studies to examine the importance of cellular interactions and gene expression in
the BBB44. Because the various cell types of the NVU have now been established,
models have been developed utilizing more than two cell types to more accurately
recapitulate BBB properties in vitro. Lippmann et al. (2011) co-cultured differentiated
rat neural progenitor cells with rat brain microvascular endothelial cells to more
effectively elevate and recapitulate BBB properties in endothelial cells compared to the
more tediously acquired primary rat astrocyte cell co-culture models45. It is important to
consider the strengths and weaknesses of each of these models when asking questions
about BBB development. In recent years, the zebrafish (Danio rerio) has emerged as a
suitable model organism for studying blood-CNS barriers.
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Zebrafish as a Model Organism
Zebrafish are genetically tractable vertebrates with high fecundity. Offspring
mature rapidly, outside of the mother, allowing for manipulation early in development.
Within 26 hours post-fertilization (hpf), zebrafish embryos already have developing eyes,
a brain, heartbeat and circulation. Their transparent nature also allows for the
visualization of these early processes in real time (Figure 1-2), making zebrafish an
excellent model for developmental biology studies. Zebrafish are a member of the
teleosts, a class of fish that underwent a genome duplication event during the course of
evolution but still have a similar number of chromosomes to humans46. Due to
conservation in genomic structure, vertebrate body plan, and systemic biology, zebrafish
are popularly used in genetic screens to uncover genes orthologous to human47.
Since the first small-scale mutagenesis screen in the early 1990s, zebrafish have
been exploited for large-scale mutagenesis screens, whole-genome sequencing, positional
cloning, insertional mutagenesis, germline transgenesis, and modeling human disease47.
Forward genetic screens surged during the 1990s in Boston, Massachusetts and
Tübingen, Germany, initially uncovering genes essential for embryogenesis48,49. This
approach identifies point mutations randomly arrayed throughout the genome based on
phenotypic screening. Forward genetic screens have identified mutants in signaling
pathways involved in various aspects of physiology such as vision, tumorigenesis, and
angiogenesis50-52. While it is more cost effective and easier to produce large zebrafish
clutches for forward genetics, zebrafish are still used for reverse genetic approaches just
as rodents are. With the advancement of technology, reverse genetics in fish is possible
with a variety of techniques such as morpholinos, Targeting Induced Local Lesions in
Genomes (TILLING), Zinc finger nucleases, transcription activator-like effector
nucleases (TALENS), and CRISPR/Cas9 systems53-55. Human mutations have also been
introduced in the zebrafish that cause the same diseases derived in human. Mutations in
BRAF(V600E) from human melanoma introduced into the fish also caused the disease
and identified molecular regulators to accelerate the malignancy, suggesting a
conservation of genes between zebrafish and mammals56. Zebrafish are not only ideal for
these genetic screens but for chemical assays as well.
Chemical screens are targeted, high-throughput platforms that have been
extensively validated with the zebrafish model system57. These assays provide a
powerful tool for therapeutic discovery as compound libraries are administered to
multiple, whole vertebrates in a multi-well format. The power of zebrafish genetics is
also commonly utilized for chemical biology studies. Chemical libraries may be applied
to genetic mutants to rescue disease-related phenotypes as well as validate structureactivity relationships57. Previous zebrafish chemical screens have identified compounds
that affect signaling pathways such as Bone Morphogenic Protein (BMP), cell cycle
progression, and cancer angiogenesis58-60.
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Figure 1-2. Zebrafish are a suitable model organism for studying developmental
biological processes
At 1 days post-fertilization (dpf), the zebrafish embryo already has a developing ear (red
arrow), brain (black arrowhead), eye (black arrow) and beating heart (red asterisk).
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Zebrafish as a Model to Study Blood-Brain Barrier Development
Within the past decade, scientists have exploited the advantages of the zebrafish
model system to study the BBB. Other groups as well as our own have demonstrated the
zebrafish BBB is comparable to that in mammals. The zebrafish BBB possesses tight
junctions anchored between BBB endothelium maintaining a physical barrier and
chemical transport systems mediating active efflux and prohibiting xenobiotic entry 61-66.
The tight junction protein Claudin5 is the most highly expressed homolog of the Claudin
family in zebrafish67. Knockdown of Claudin5a in zebrafish reduces ventricle lumen
expansion but does not affect neuroepithelial tissue integrity68. The zebrafish genome
duplication event resulted in Claudin5a and Claudin5b alleles. Each paralog’s tissue
specificity has not been fully resolved and this may explain why Claudin5a knockdown
may have an effect on the blood-CSF barrier and not at the BBB67. Functional studies in
zebrafish are starting to occur as Fischer et al (2013) recently demonstrated the influx of
the substrate Rhodamine with chemical and genetic inhibition of zebrafish abcb4, what
they deem as the zebrafish ortholog to MDR166. Further investigation of bioavailability
of compounds at the BBB still needs to be established. Zebrafish possess multi-drug
resistance proteins in the gut epithelium and can actively prohibit the absorption of
doxorubicin, a common MDR1 substrate65. Because the gut lumen and BBB maintain a
similar barrier phenotype, it is possible that Mdr1 expressed at the zebrafish BBB also
excludes compounds similarly69. All of these properties confer a functional BBB as it
has been established in mammalian models61.
Neural vascular biology correspondingly develops in fish as it does in mammals
(Figure 1-3). Development of the zebrafish primordial hindbrain channels (PHBC)
commences around 28 hpf in the zebrafish brain similarly as the formation of the
perineural vascular plexus around E8.5 in the mouse and E11 in the rat27,35,70. Growth
factors, including vascular endothelial cell growth factor (VEGF) signaling, have been
widely established as important and specific mitogens in vessel formation71.
Heterozygous lethality of one VEGF allele demonstrates the importance of this signaling
pathway in blood vessel development72. Various zebrafish VEGF mutants also
demonstrate genetically distinct VEGF profiles for particular blood vessel types73.
After vasculogenesis, nascent blood vessels sprout into the developing brain
parenchyma. This process of newly formed vessels budding off of pre-existing ones is
called angiogenesis74. Our lab has demonstrated CNS angiogenesis occurs similarly at
30hpf from zebrafish PHBCs as it does from the mouse perineural vascular plexus at
E9.5-1035,36 (Taylor lab, data unpublished). In the zebrafish, the main arterial route and
vessel branching becomes hearty by 2 dpf70. In addition to CNS angiogenesis, markers of
barriergenesis also differentiate similarly in the zebrafish. GLUT1 has been identified as
one of the initial markers of cerebral angiogenesis in mammals appearing at E12 in rat
and E11 in mouse BECs28,75. Zebrafish also specifically express Glut1 early in
angiogenesis suggesting that brain endothelial cells differentiate during initial CNS
angiogenesis64 (Taylor lab, data unpublished). Recently, it has been established that
zebrafish express brain pericytes ensheathing endothelium as early as 48 hpf and
brain development76,77. The difference in timing of pericyte versus astrocyte

9

Figure 1-3. Comparative timeline of events between zebrafish and mammals
during blood-brain barrier development
Zebrafish vasculogenesis, CNS angiogenesis, and barriergenesis occurs similarly as it
does in rodents. The literature suggests that these two processes occur simultaneously,
but a model has yet to show this in real time. The advantages of the zebrafish model
system could be used to more carefully dissect these processes.
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development in the zebrafish brain may be an artifact of evolution, lack of transgenic
lines to look at pericyte development in real time, as well as a limitation on established
zebrafish astrocyte markers. For example, grey matter “protoplasmic” astrocytes
surrounding CNS blood vessels express distinctive markers from the fibrous astrocytes
that are typically labeled with the commonly used glial fibrillary associated protein
marker78.
Zebrafish provide an excellent model system for identifying canonical signaling
pathways as well as novel signals important to development. Interestingly enough,
expression profiles in mouse brain vasculature can be exploited in the zebrafish BBB.
Tam et. al (2012) demonstrated the death receptors DR6 and TROY are important for
both mouse and zebrafish barriergenesis64. These death receptors were also shown to be
regulated by Wnt signaling, suggesting conservation in BBB signaling pathways between
mammals and zebrafish64. Notch signaling has also been identified as an important
regulator of barriergenesis in the mouse and has now been validated in the zebrafish76,79.
The field of brain barrier biology could therefore benefit from further exploiting the
zebrafish model system to uncover novel signaling pathways in high-throughput genetic
and chemical screens.
Hypothesis and Scope of This Dissertation
The ultimate goal of this project was to use the zebrafish model for unbiased
genetic and small molecule screens. These in vivo strategies could uncover novel
molecular constituents that are important in barriergenesis. Therefore, we hypothesized
that zebrafish can be used to genetically dissect the molecular mechanisms important for
the development, function and maintenance of the BBB. To test our hypothesis, we
completed the following specific aims:
1. Produce a BBB reporter line to characterize the in vivo development of the
BBB.
We hypothesize that the creation of transgenic reporter lines using genes
important for barrier function will allow us to study the development of the BBB. We
first plan to create and then characterize the BBB reporter line, to survey the in vivo
development of the BBB. By performing proof-of-principle experiments on our
transgenic model, we can demonstrate that this reporter is a powerful tool for studying
BBB development in a live animal and therefore useful for high-throughput screens.
2. Perform a genetic dissection of the BBB to uncover novel molecules that
affect BBB properties.
A forward genetic and chemical screen exploiting our BBB reporter line could
uncover mutants and compounds that cause defects in CNS angiogenesis and reporter
expression. We will perform a small-scale F3 genetic screen after ENU treatment of
adult BBB transgenics. Simultaneously we will test different compound libraries in wild-
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type BBB transgenics to look for alteration in BBB structure and reporter expression.
These approaches are not only unbiased, but present the possibility of uncovering
unfamiliar mechanisms important in barriergenesis. The execution of this screen will not
only advance our understanding of BBB development but potentially reveal new genes
from cloning mutants and “hits” that could be targeted for CNS drug therapy.
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CHAPTER 2.

GENERATION OF A BLOOD-BRAIN BARRIER REPORTER
LINE
Introduction

Transgenics Used to Study the Blood-Brain Barrier
Transgenic animals are modified to express non-native genetic sequences and
have been studied to investigate developmental processes, tissues, and disease47,80,81.
These models are typically constructed by placing a specific promoter sequence upstream
of a gene that will express some bioluminescent or fluorescent protein. However, there
are currently no published models to study the BBB whereby a promoter localizes a
reporter gene only to BECs. Instead, many groups utilize endothelial cell promoters to
study BEC development even though all blood vessels are labeled. For example, the
Tie2-GFP line is commonly used to study BBB development in the mouse35,36,40. The
Tie2 promoter, an endothelial specific receptor tyrosine kinase, was used to create and
understand vascular endothelial cell growth and function 82. Studies for zebrafish BBB
development have also utilized a similar transgenic line, Tg(fli1a:EGFP)y1 (herein
Tg(fli1a:EGFP)) which labels blood vessels throughout the whole organism with the
friend leukemia virus integration 1a (fli1a) promoter driving expression of the enhanced
green fluorescent protein (EGFP) reporter gene 61,80,83. These transgenics are sufficient to
study vessel development, but their promoter sequences are not specific to brain
endothelium. More recently, the Tg(l-fabp:DBP-EGFP) zebrafish reporter was generated
to study the development and maintenance of brain barriers based on the expression and
circulation of a 78 kDa (kilo Dalton) Vitamin-D binding protein fused to EGFP62. The
Tg(l-fabp:DBP-EGFP) line was useful for studying the functional development of the
BBB however, this transgenic does not report on the barrier signals that are essential for
maintaining BBB function. If a BBB reporter line existed, studies could be performed to
target pathways that affect molecular properties that constitute BECs versus signals that
pertain to all endothelium. Therefore, the field of BBB biology could benefit from the
construction of a zebrafish BBB reporter line.
Tol2 Transgenesis
To generate tissue specific reporter lines, zebrafish labs commonly use the
Tol2Kit.84 This system is ideal for transgenesis as compared to injection of regular
plasmid Deoxyribonucleic Acid (DNA) which gives lower germline transmission rates.84
Construct integration with Tol2 can also be visualized by fluorescent reporter gene
expression. It has been established that the Medaka fish, Oryzias latipes, possesses a
transposable system deemed Tol2-tyr which can move in a cut and paste manner.85
While zebrafish do not contain Tol2 elements, co-injection into single cell zebrafish
embryos of a Tol2 element with Tol2 transposase transcribed in vitro results in germ-line
integration of the Tol2 element.86 The Tol2Kit uses site-specific recombination-based
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cloning that can produce a final clone containing a promoter sequence upstream of a
reporter gene.84 Based on previous reports of the Tol2 system, a transgenesis rate of 50%
is expected.87 Furthermore, the Tol2Kit has successfully produced transgenics such as
those using the bactin2 and hsp70 promoters to drive GFP expression.84
Materials and Methods
Zebrafish Lines
The Tg(fli1a:EGFP) strain was acquired from the Zebrafish International
Resource Center (ZIRC). To assess glut1b expression patterns, we used two other
transgenics, cp:EGFP, an enhancer trap line generated in our lab that expresses EGFP in
the choroid plexus and tαc:EGFP, a transgenic line that expresses EGFP in photoreceptor
cells and the pineal gland. Embryos and larvae were maintained at 28.5oC in egg water
(0.03% Instant Ocean). 0.003% N-Phenylthiourea (PTU) was used to inhibit melanin
production for imaging. Dr. Taylor injected 2 nl of 1 mg/ml bovine serum Albumin,
Alexa Fluor 647 Conjugate (Invitrogen) into the common cardinal vein and fish were
imaged by confocal microscopy
Tol2 Transgenesis and Construct Microinjection
The generation and injection of the BBB construct was performed in a group
effort by multiple lab members. To generate the construct for Tg(glut1b:mCherry)sj1,we
used Gateway compatible vectors of the Tol2kit. A 2.9 kb fragment of the zebrafish
glut1b promoter (accession #: NM_001039808) was amplified from genomic DNA using
a forward primer of 5’-TATTctcgagGGGGCTGATAACATTGACCT (with a Xho I
restriction site added, lower case) and a reverse primer of 5’TCCAggatccCAAAAATTGTTCTTTAAAAAAAAC (with a Bam HI site added, lower
case) and subcloned into the TOPO TA cloning vector (Invitrogen). The glut1b promoter
was released from the cloning vector by XhoI and BamHI double digestion and inserted
into p5E-MCS (Tol2kit). This 5’ entry clone was combined with middle entry clone
pME-mCherry, the 3’ entry clone p3E-polyA, and the pDestTol2pA2 destination vector to
create the pDest-glut1b:mCherry construct using the LR Clonase II Plus Enzyme mix
(Invitrogen). Approximately 30 pg of plasmid DNA and 30 pg of in vitro transcribed
Tol2 transposase messenger ribonucleic acid (mRNA) were co-injected into single-cell
Tg(fli1a:EGFP) embryos ( n= 45). All microinjections were performed using a PV820
Pneumatic PicoPump (WPI). The embryos were raised to adulthood and screened for
germline transmission by observing mCherry expression in BECs. The
Tg(glut1b:mCherry)sj1 line was bred to homozygosity and determined to contain a single
insertion site.
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Live Imaging Confocal Microscopy
For imaging, fish (1-6 dpf) were anesthetized in 0.02% Tricaine and immobilized
in 1.2% low melting point agarose (Invitrogen) in glass bottom culture dishes (MatTek).
Confocal microscopy was performed on a Nikon TE2000E2 microscope equipped with a
Nikon C1Si confocal using 488nm, 561nm and 638nm DPSS lasers for excitation.
Images were acquired with a Nikon 20X 0.75 NA Plan Apo DIC objective and processed
using Nikon NIS Elements software. Confocal z stacks were acquired with a 3 micron
step size; for time-lapse imaging, a z stack was acquired every 30 minutes for 30 hours.
All images are 2D projections of 3D confocal z-stacks, generated using either a MIP or
EDF algorithm. Time-lapse movies were further processed by applying a Gaussian blur
to the image stack before creating the 2D projection in order to remove “noise” from the
collection of pixels.
Adult Dissection
Tg(fli1a:EGFP) and Tg(glut1b:mCherry) adults were deeply anesthetized with
0.04% tricaine made in system water and humanely sacrificed for dissection. Dissections
were performed on a petri dish containing a Kim wipe soaked in 0.04 % tricaine. Tissues
were dissected using a razor blade and fine forceps. Organ images were acquired on a
Nikon SMZ 1500 stereoscope with a PRIOR Scientific Lumen 200 PRO Fluorescence
Illumination System.
Results and Discussion
Selecting a BBB-Promoter, Glucose Transporter 1
BECs possess chemical and physical barriers to maintain brain homeostasis. The
chemical barrier is mediated by transport systems, which may be metabolic, xenobiotic or
solute specific. Carrier-mediated efflux pumps are crucial for delivering nutrients to the
brain that would not otherwise be accessible. Glut1, one of these main transporters, is
responsible for delivering glucose to the brain, as it requires 20% of whole body
glucose26. Because of this physiological need, GLUT1 is highly expressed at the
BBB.7,39,88 GLUT1 is also one of the earliest markers at the BBB, and several recent
studies have used GLUT1 expression as a functional indicator of BBB formation36,41. It
has also been reported that BBB tightness plays a pivotal role in the pattern of GLUT1
expression during brain differentiation, demonstrating that GLUT1 serves as an indicator
of BBB function as well as development28,75. Furthermore, it has been demonstrated that
Glut1 localizes to BECs in zebrafish64. Therefore, based on its significance in BBB
development and expression, we selected the zebrafish Glut1 homolog as a molecular
tool for creating our BBB transgenic line.
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To visualize in vivo development of the BBB, we created a novel transgenic
zebrafish reporter line using the zebrafish glut1b promoter. While zebrafish have three
glut1 paralogs, we focused our studies on glut1b (NM_001039808), due to its
predominant expression of mRNA in the brain63. We chose mCherry for our BBB
reporter because it matures more rapidly than other fluorescent proteins (t0.5=15 minutes)
allowing for accurate observation of temporal expression89. Injections were performed in
the Tg(fli1a:EGFP) line so we could look for an overlap with glut1b expression in EGFP
positive BECs (Figure 2-1). Generating the BBB line with a transgenic labeling all
endothelium would also allow us to study processes that affect BECs separately from the
periphery. We found mCherry transiently expressed in the brain vasculature of ~90% of
injected embryos (Figure 2-2).
Visualization of BBB in vivo Development
We identified several stable transgenic lines by out-crossing transient expressers
to Tg(fli1a:EGFP) and designated one as Tg(glut1b:mCherry)sj1 (herein
Tg(glut1b:mCherry)). To characterize the expression pattern of mCherry, we used
confocal laser scanning microscopy on live glut1b:mCherry; fli1a:EGFP double
transgenics. At 6 dpf, mCherry was expressed specifically in the brain vasculature
(Figure 2-3C) and in the myocardium (data not shown), but not in the peripheral
vasculature (Figure 2-3F). This expression pattern was maintained in adulthood as well
as in the reproductive tissues of the adult (Figure 2-4). GLUT1 is expressed in ovarian
tissue among different species, yet there are still species specific differences in tissue
expression patterns90. When the cavities of the adults were opened, it appeared as if
viscera like the kidney (data not shown) may also be glut1b positive which has also been
reported in other species as glucose transport is involved in hyperglycemia and diabetes
progression91.
Brain vessels are very specialized so that they do not easily allow the free
exchange of molecules into the brain. One of these specializations includes the lack of
fenestrations, openings in the vessel wall, a non-barrier property which is commonly seen
in circumventricular organs92. Fenestrations are not only present in these organs but have
also been demonstrated as marker for BBB disruption93. To demonstrate that mCherry
expression was specific to endothelium that maintain BBB properties, we looked at
mCherry in circumventricular organs in other transgenic lines. We crossed
Tg(glut1b:mCherry) to cp:EGFP, an enhancer trap line that expresses EGFP in the
choroid plexus and tαc:EGFP, a transgenic line that expresses EGFP in the pineal gland.
We found that mCherry was not expressed in the choroid plexus or pineal gland
vasculature (Figure 2-3J and N), indicating that glut1b:mCherry in the zebrafish
faithfully recapitulates mammalian GLUT1 expression at the BBB.
Taking advantage of our in vivo model, we wanted to address a fundamental
argument about BBB development. Ongoing hypotheses suggest that BBB formation is
either 1) a two-step process where CNS angiogenesis occurs and is followed by
barriergenesis, or that 2) both CNS angiogenesis and barriergenesis occur at the same
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Figure 2-1. Blood-brain barrier construct injection into Tg(fli1a:EGFP)y1
embryos
A BBB reporter construct was engineered with the Gateway Tol2kit cloning system.
This DNA element contained a 2.9kb fragment of the zebrafish glut1b promoter upstream
of the mCherry reporter gene. The DNA construct contained Tol2 sites flanking the
transgene, so that upon co-injection with Tol2 transposase mRNA into single cell
Tg(fli1a:EGFP) embryos, the construct would be inserted into the genome of the
developing zebrafish. We hypothesized that if the glut1b promoter was specific to BECs,
we would see a yellow overlay with the red signal from glut1b and the green signal from
fli1a.
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Figure 2-2. Transient expression of glut1b:mCherry in fli1a:EGFP brain
endothelium
After co-injection of the Tol2 transposase mRNA and the glut1b construct,
glut1b:mCherry localized to fli1a:EGFP BECs as seen here with a representative 3 dpf
transgenic animal (anterior, right; dorsal, top). Transient expression also reveals that the
promoter does not localize mCherry to peripheral blood vessels.
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Figure 2-3. glut1b is expressed in brain endothelial cells and not in
circumventricular organs
Upon germline transmission of the glut1b:mCherry transgene, mCherry was still
restricted to the brain vessels of a 6 dpf animal (C) and not the peripheral vasculature (F).
We crossed Tg(glut1b:mCherry) to two other transgenics that expressed EGFP in tissues
that have fenestrated endothelium, the choroid plexus (H arrows and arrowhead) and
pineal gland (L arrowhead ). These lines were also injected with an Albumin tracer
labeled in the far red channel to demonstrate that these BECs were functional. As seen
from the merge panels, glut1b is not expressed in capillaries of the choroid plexus (J) or
pineal gland (N).
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Figure 2-4. glut1b:mCherry is maintained in adult brain endothelial cells as well
as reproductive tissues
Tg(fli1a:EGFP) (left tissues) and Tg(glut1b:mCherry) (right tissues) adults were
dissected to look at glut1b expression in adulthood. glut1b still localized to BECs in
adulthood and was also seen in reproductive tissues like the ovaries and testes.
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time. The “two-step” hypothesis is largely based upon observations that immature CNS
blood vessels are leaky to injected tracers such as Evans Blue. However, the conclusions
from these studies have been challenged due to the methodology used1. While growing
evidence indicates that barriergenesis and CNS angiogenesis may be linked, the inability
to visualize these processes in real time limits the observation of the earliest steps of CNS
vascular development36. To address this issue, we performed time-lapse confocal
microscopy to examine the temporal induction of barrier properties. In zebrafish, CNS
angiogenesis begins in the hindbrain at approximately 30 hpf when endothelial tip cells
originating from the PHBCs migrate into the brain parenchyma70. These vessels
eventually form the central arteries (CtAs) that interconnect the PHBCs with the basilar
artery. Using live glut1b:mCherry; fli1a:EGFP double transgenics, we imaged
angiogenesis and barriergenesis from 30 to 60 hpf. We observed that endothelial cells
express mCherry immediately upon entering the brain (Figure 2-5), indicating direct
evidence for the hypothesis that barriergenesis and angiogenesis occur simultaneously.
Conclusion
A comprehensive understanding of the development and maintenance of the BBB
has been hampered by difficulties in observing the BBB in vivo. To do this, we generated
a transgenic zebrafish line, Tg(glut1b:mCherry)sj1, to serve as an in vivo reporter of the
BBB. These animals were used for imaging live BBB formation, a process that has not
been able to be performed until now. We show that our transgenic line drives expression
just like the mammalian GLUT1 ortholog, specifically in BECs and not in the vasculature
of peripheral tissues or circumventricular organs with fenestrated capillaries. This
expression pattern is maintained until adulthood as well. Furthermore, we show evidence
for the first time that the processes of barriergenesis and angiogenesis happen
concurrently in a live animal.
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Figure 2-5. Angiogenesis and barriergenesis occur simultaneously
Stills were taken from a live time-lapse movie of glut1b:mCherry development. As soon
as fli1a:EGFP positive tip cells migrated into the zebrafish brain parenchyma at 30 hpf,
the endothelium turned positive for glut1b:mCherry expression. This expression is
visualized over the 30 hour movie.
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CHAPTER 3.

CHARACTERIZATION OF THE BLOOD-BRAIN BARRIER
REPORTER LINE*
Introduction

Characteristic Properties of the BBB
The BBB is well-known for restricting xenobiotic entry into the CNS while still
providing the proper nutrition for brain tissue. Since the start of the 20th century, the
BBB has been known to maintain a functional partition between the circulatory system
and the CNS17-19. It was not until quite some time later, that seminal transplant studies
elucidated the importance of the brain milieu for a functional barrier32. Electron
microscopy later revealed that tight junction proteins in between brain endothelium
regulate the passive transport of substances into the brain tissue21. Multi-drug resistant
proteins found up-regulated in cancerous tissues were also found localized to BECs as a
mechanism to explain poor drug penetration in the brain8. Localization of transport
systems in the BBB was also congruent with the highly metabolic nature of the brain28,75.
Together, these specific proteins located along the brain endothelium are what give the
BBB its special properties and function.
Methods for Testing the Function and Structure of the BBB
Functional Protein Markers. The features responsible for creating the physical
and chemical barriers in the CNS have been widely established and are used as traditional
markers of BBB integrity. In addition to studying the normal protein expression of each
of these markers, multiple knock-out animals have been generated to assess their
biological contributions to CNS barriers22,24,94,95. Tight junction proteins anchored
between BECs are responsible for regulating the free exchange of factors that circulate
between the blood and the CNS. Tight junctions compose an intricate network to tether
brain endothelium and are vulnerable to destruction in various disease states2. In fact,
each Claudin family member regulates the access of different sized molecules2,22.
Claudins are expressed early in zebrafish development and lack of functional Claudin
affects the blood-CSF barrier62,67. The ABC transporter family proteins, BCRP and
MDR1 are two of the most widely studied features in the chemical barrier that maintain
drug distribution throughout the BBB7. While these proteins have been thoroughly
established in the mammalian BBB, recent zebrafish work has demonstrated the presence
of multi-drug resistance proteins in fish as well65,66,96. Studies have also used the
*Modified with permission. Umans, R. A. & Taylor, M. R. Zebrafish as a model to study
drug transporters at the blood-brain barrier. Clin Pharmacol Ther 92, 567-570,
doi:10.1038/clpt.2012.168 (2012).
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expression of carrier-mediated transporters like GLUT1 to demonstrate functional
integrity of the BBB27,75. In fact, GLUT1 haploinsufficiency results in high brain
dysfunction and elucidates the importance of this transport system in the CNS2.
Tracer Injections. Erhlich’s tracer injections between brain and the CSF were
what initially identified a barrier between the blood and CNS17,18. Additional trypan blue
injections performed by his graduate student in the early 20th century helped further
establish the functional compartment between the blood and CSF19. Injections with
trypan and Evans blue are not antiquated and still typically performed to assess the
development of the BBB and its function in disease states27,97. However, caution should
be taken when assessing these results as large injection volumes may cause staining of
the brain in instances smaller volumes would not1. With the advancement in imaging
techniques, fluorescence microscopy is also commonly used to look at the integrity of the
BBB. Functional studies have utilized circulating proteins or tracers conjugated to
fluorescent dextrans to visualize BBB function which is ideal in the optically transparent
zebrafish system35,40,61.
Materials and Methods
Immunohistochemistry (IHC)
These experiments were performed in conjunction with the other graduate
research assistant, Dr. Hannah Henson. For tissue sectioning, embryos were fixed in 4%
paraformaldehyde overnight at 4ºC, washed in 1x Phosphate Buffered Saline (PBS), and
stored in 30% sucrose at 4ºC. Embryos were embedded in OCT and stored at -20 ºC.
Tissue sectioning was performed using a Leica CM 1950 cryostat. Transverse sections
were done on 30hpf and 36hpf embryos and coronal sections were done on 48hpf-6dpf
embryos.
For Glut1 and Mdr1 immunohistochemistry, primary antibodies included rabbit
anti-Glut1 (1:200; Novus Biologicals) mouse anti-GFP (1:500; Invitrogen), mouse antiMdr1 (1:20, Calbiochem), and rabbit anti-GFP (1:500, Invitrogen). Secondary antibodies
included goat anti-rabbit 555 (1:400; Invitrogen), goat anti-mouse 488 (1:1000;
Invitrogen), goat anti-mouse 555 (1:200, Invitrogen), and goat anti-rabbit 488 (1:200,
Invitrogen). Antibody dilutions were prepared in 1xPBS/Triton 0.03% (PBST). Sections
were washed in 1x PBS for 5 minutes and in PBST 3 times for 5 minutes. Blocking was
done in 5% goat serum and incubated for 3 hours at room temperature. Primary
antibodies were added overnight at 4ºC. Secondary antibodies were added for 2 hours at
room temperature. Washes in PBST were performed after primary and secondary
antibody incubations. Sections were DAPI stained, rinsed briefly in 1x PBS, and
mounted with Fluoromount (Electron Microscopy Sciences) before adding the coverslip.
All images were taken on a Nikon AZ100 microscope using NIS-Elements AR 3.2
software.
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Live Imaging Confocal Microscopy
For imaging, fish (1-6 dpf) were anesthetized in 0.02% Tricaine and immobilized
in 1.2% low melting point agarose (Invitrogen) in glass bottom culture dishes (MatTek).
Confocal microscopy was performed on a Nikon TE2000E2 microscope equipped with a
Nikon C1Si confocal using 488nm, 561nm and 638nm DPSS lasers for excitation.
Images were acquired with a Nikon 20X 0.75 NA Plan Apo DIC objective and processed
using Nikon NIS Elements software. Confocal z stacks were acquired with a 3 micron
step size. All images are 2D projections of 3D confocal z-stacks, generated using either a
MIP or EDF algorithm. Time-lapse movies were further processed by Dr. Jennifer Peters
by applying a Gaussian blur to the image stack before creating the 2D projection.
Transgenic Wnt Inhibition by Induction of Axin-1
Embryos from a Tg(glut1b:mCherry;fli1a:EGFP) female crossed to a Tg(hsp70l1:GFP-Axin1)zd13 (herein Tg( hsp70l-1:GFP-axin1)) male were transferred into a 1.5 ml
centrifuge tube with 0.5 ml egg water/PTU and placed in a heating block set to 38oC.
Heat shock was performed at 24 hpf and 48 hpf for either 30 min or 60 min each.
Tg(glut1b:mCherry) embryos express mCherry in early development due to maternal
deposits that obscure mCherry expression in BECs up to 3 dpf. Thus, the effects of heat
shock-induced Axin1 could not be easily visualized prior to 3 dpf. Therefore, a second
heat shock at 48 hpf was necessary to maintain sufficient levels of Axin1 for imaging at
78 hpf.
Small Molecule Treatment with VEGFR Inhibitors
These experiments were performed by Dr. Michael Taylor. For drug treatments,
AV-951 (Selleckchem), DMH1 (Tocris), DMH4 (Sigma), and Cyclopamine (Sigma)
were prepared as stocks in 100% DMSO at 10 mM and applied to 24 hpf embryos at a
final concentration of 1 µM, 10 µM, 10 µM, and 50 µM, , respectively.
Troponin (tnnt2a) Morpholino
We generated a tnnt2a morpholino (Gene Tools) using the previously published
morpholino sequence98. A 2 mM stock of morpholino was prepared upon receiving the
lyophilized powder from Gene Tools. The stock was heated up at 55 °C for 5 minutes,
allowed to cool down, and then prepared with 1% phenol red for injection.
Approximately 4 ng of tnnt2a morpholino was injected into single-cell embryos from a
Tg(glut1b:mCherry)sj1; Tg(fli1a:EGFP)y1 male X TL female cross, resulting in >90% of
embryos with no heartbeat. Embryos were imaged at 2 dpf.
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Albumin Alexa Fluor 647 Injection
For tracer microinjection, Dr. Michael Taylor injected 2 nl of 1 mg/ml bovine
serum albumin, Alexa Fluor 647 Conjugate (Invitrogen) into the common cardinal vein
and imaged by confocal microscopy. All microinjections were performed using a PV820
Pneumatic PicoPump (WPI). Injection volumes were calculated using a 0.01 mm Stage
Micrometer (Fisher Scientific).
Results and Discussion
Characterization of Zebrafish BBB Development
After we achieved stable germline transmission with Tg(glut1b:mCherry),
animals were mated to homozygosity. Our next goal was to perform proof-of-principle
experiments to demonstrate the usefulness of our BBB reporter and that the BBB is
comparable in fish and in mammals. To do so, we performed experiments to take
advantage of the zebrafish’s transparency, genetic tractability and ease in chemical
treatment.
IHC with BBB Markers. We examined the zebrafish brain microvasculature for
the presence of endothelial tight junctions and the expression of transporters localized to
BECs. We found that zebrafish BECs express the tight junction protein Claudin 5 and the
transporter Glut1 as early as 2 dpf, consistent with previous studies (Figure 3-1)62,64.
Furthermore, we demonstrated for the first time that zebrafish BECs express the drug
efflux transporter, Mdr1 throughout development (Figure 3-2)65. Together, these
observations indicate that the zebrafish expresses BBB markers as do mammals.
Function of Newly Formed Vessels. We next examined the integrity of newly
formed brain vessels since zebrafish are amenable to early embryonic visualization. We
injected Albumin, Alexa Fluor 647 conjugate as a semi-endogenous permeability tracer
into the cardinal vein of Tg(glut1b:mCherry; fli1a:EGFP) double transgenics prior to
CNS angiogenesis and imaged from 30 to 60 hpf. We found that albumin was contained
within the lumen of the vasculature as new vessels migrated into the brain parenchyma
(Figure 3-3). These results show that physical barrier properties are present even at the
earliest stages of brain vascular development, a hypothesis that is widely debated1.
However, during this time course, some albumin appeared to enter the brain ventricles
(Figure 3-3 asterisks). This ventricular “leakage” is likely due to the lack of a functional
choroid plexus, which develops at 4 dpf in zebrafish and is consistent with the lack of
barrier properties in the choroid plexus vasculature at later developmental stages99,100.
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Figure 3-1. Zebrafish brain endothelial cells express Claudin5 and Glut1 during
development
Tg(fli1a:EGFP) animals were sectioned to look at the co-localization of BBB markers to
EGFP positive blood vessels. Just as the mammalian BBB, embryonic, larval, and adult
zebrafish express tight junction proteins like Claudin5 (A) and efflux transporters like
Glut1 (B) in BECs.
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Figure 3-2. Zebrafish brain endothelial cells express Mdr1 during development
Tg(fli1a:EGFP) animals were sectioned to look at the co-localization of Mdr1 to EGFP
positive blood vessels. Sections reveal that zebrafish express one of the main BBB
transports, Mdr1, in BECs over the course of development.
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Figure 3-3. Newly formed vessels are impermeable to albumin
Tg(glut1b:mCherry;fli1a:EGFP) embryos were injected with Albumin conjugated to an
Alexa Fluor 647 prior to CNS angiogenesis and visualized with live confocal imaging
microscopy. These stills from the movie reveal that nascent glut1b positive blood vessels
retain the large tracer when they migrate into the brain unlike the blood-CSF barrier
(asterisks).
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Signals that Regulate Barriergenesis
Wnt Signaling. Wnt is a classical signaling pathway important for the initial
stages of embryonic development but has also underlies the role in the health and
differentiation of blood vessel morphogenesis 101. Recent studies in mice have shown
that canonical Wnt/β-catenin signaling plays a critical role specifically in CNS
angiogenesis and BBB development36,102. However, the onset of barriergenesis is
difficult to resolve in these models due to embryonic lethality, the lack of normal CNS
blood vessels, and the inability to visualize development in vivo. Therefore, to examine
the effects of Wnt signaling on barrier formation in zebrafish, we crossed
Tg(glut1b:mCherry; fli1a:EGFP) to Tg( hsp70l-1:GFP-axin1), a transgenic line that
allows for heat shock-dependent expression of Axin1, a potent inhibitor of Wnt
signaling103. Modulation of heat shock parameters allowed for temporal and graded
induction of Wnt inhibition. We performed heat shock for 60 minutes on the triple
transgenic embryos and examined the effects at 3 dpf. While heat shock had no effect on
control embryos without the axin-1 transgene (Figure 3-4C), we found that induction of
Axin1 for 60 minutes completely inhibited angiogenesis and resulted in displaced
mCherry expression (Figure 3-4G). These results are consistent with studies using
conditional mouse knockouts of Wnt signaling, where Glut1 is ectopically expressed36.
To determine if we could dissect the contribution of Wnt signaling to both
angiogenesis and barriergenesis, we reduced the duration of heat shock to 30 and 15
minutes. While 15 minute heat shock had no obvious effect (data not shown), we found
that 30 minute heat shock was permissive for angiogenesis, but significantly inhibited
mCherry expression (Figure 3-4K). These data indicate that there may be a Wnt
signaling gradient that differs between angiogenesis and barriergenesis and that the level
of inhibition may reflect differences in the expression of specific Wnt target genes.
Differences in expression may explain why a canonical pathway has such a tissue
specific phenotype. This interpretation of our results is also consistent with previous
work demonstrating that specific Wnt ligands are spatiotemporally expressed throughout
the developing mammalian brain and variably affect barriergenesis36.
VEGF, Shh, and BMP Signaling. As an additional proof-of-principle, we
wanted to look further into signaling pathways important for mammalian barriergenesis
in our zebrafish BBB model. With live imaging, we witnessed that barrier properties
were present as soon as BECs migrated into brain tissue. Furthermore, we hypothesized
that if CNS angiogenesis and barriergenesis were linked, then barrier properties should
not be inducible in the absence of angiogenesis. This idea is commonly seen in BBB
rodent studies, where knocking out genes important for barrier properties simultaneously
disrupts CNS angiogenesis35,36 . To test this interpretation, we chemically inhibited
angiogenesis after the initial stages of development but before CNS angiogenesis
occurred. At 24 hpf, we added the potent VEGF Receptor antagonists AV-951
(Tivozanib) and DMH4 to our BBB transgenic line and imaged the embryos after a 24
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Figure 3-4. Levels of Wnt inhibition are permissive for angiogenesis but not
barriergenesis
Transgenic hsp70I-1:GFP-axin1;glut1b:mCherry;fli1a:EGFP or
glut1b:mCherry;fli1a:EGFP control embryos underwent heat shock at 24hpf at 38°C to
deduce whether Wnt signaling was required for barrier properties in the developing
zebrafish BBB. As seen in mice, 60 minute heat shock obliterated CNS angiogenesis and
therefore barrier properties in the zebrafish BBB (G). However, titrating Axin-1
induction back to a 30 minute heat shock allowed CNS angiogenesis to occur without
barrier properties (K), suggesting that Wnt signaling is required for the initiation of
barrier formation but not CNS angiogenesis.

31

hour exposure104,105. As expected, both compounds completely inhibited CNS
angiogenesis (Figure 3-5). Surprisingly, the PHBCs, where hindbrain angiogenesis
originates, strongly expressed mCherry, indicating that Glut1 can be induced in CNS
vessels in the absence of angiogenesis (Figure 3-5). In contrast, previous work showed
that Wnt signaling was necessary for GLUT1 expression in the perineural vascular plexus
in the absence of CNS angiogenesis, thus implicating Wnt signaling in both angiogenesis
and barriergenesis31. However, our data indicate that the acquisition of barrier properties,
while dependent on Wnt signaling, is a distinct process from CNS angiogenesis and
independent of VEGF signaling.
We next examined the role of Shh and BMP signaling on barriergenesis, because
both pathways are known to be involved in vascular development106. In fact, a recent
report demonstrated that brain astrocytes secrete Shh, BECs express Shh receptors, and
concluded that the Shh pathway promotes BBB formation during embryonic development
and adulthood33. To test this finding in zebrafish, we added the Shh pathway antagonists
Cyclopamine to our transgenic line and found no obvious defects in either angiogenesis
or barriergenesis (Figure 3-6G). We also found no effects with the BMP pathway
antagonist DMH1 (Figure 3-6K). Thus, our results indicate that Shh and BMP signaling
are not required for the initial induction of barrier properties in zebrafish.
Circulation and Glut1 Expression. We also wanted to determine if vascular
circulation influenced the relationship between angiogenesis and barriergenesis. Recent
studies have shown that shear stress plays a key role in the expression of important
transporters and paracellular protein complexes that cause BEC differentiation 107.
Because zebrafish can survive early development in the absence of circulatory flow, we
injected our BBB reporter line with a morpholino antisense oligonucleotide that targets
cardiac troponin T2A (tnnt2a) mRNA98. Embryos deficient for tnnt2a have a
nonfunctional heart but little effect on CNS angiogenesis even without circulatory
flow108. Similarly, we found that tnnt2a morphants had thinner vessel lumens, most
likely due to the lack of pressure from circulatory flow. However, we unexpectedly
found that the tnnt2a morphants developed a CNS vasculature that still strongly
expressed mCherry, suggesting that circulation may not be essential for barriergenesis
(Figure 3-7). Because the vessel lumens were most likely collapsed, it is hard to
determine quantitatively if tnnt2a morphants had an actual increase in glut1b expression
as the mCherry signal may just be more concentrated due to the change in vessel
structure (Figure 3-7H). If glut1b expression was actually increased, we suspect that
hypoxia due to the loss of circulation might induce Glut1 overexpression at the BBB and
therefore be relevant in neurological diseases such as stroke.
Conclusion
In conclusion, we report the first direct observation that BBB formation is
initiated at the same time as CNS angiogenesis. Using time-lapse confocal microscopy,
we showed that barriergenesis (i.e. the initiation of BBB development) occurs

32

Figure 3-5. Angiogenesis is not required for barriergenesis to occur
VEGFR-2 antagonists 1 µM AV-951 and 10 µM DMH4 were added to 24hpf embryos
before barriergenesis. As expected, both inhibitors prevented CNS angiogenesis but to
our surprise, glut1b expression still persisted (G, K).
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Figure 3-6. Shh and BMP signaling is not required for glut1b expression in the
zebrafish blood-brain barrier
50 µM Cyclopamine and 10 µM DMH1 were added to 24 hpf
Tg(glut1b:mCherry;fli1a:EGFP) to assess the effects of Shh and BMP signaling on
barrier properties. Neither Cyclopamine (G) nor DMH1 (K) caused any effects on
barriergenesis.
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Figure 3-7. Circulation is not required for glut1b expression in the zebrafish
blood-brain barrier
Single cell Tg (glut1b:mCherry;fli1a:EGFP) embryos were injected with the tnnt2a
morpholino to assess the effects of shear stress on barrier properties. While heartbeat and
circulation were obsolete, morphants still exhibited glut1b expression (E). Morphant
vessels appeared brighter (E) compared to un-injected control siblings (A) but morphant
vessels also appeared collapsed (H) compared to control vessels (D).
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immediately as new vessels sprout into the brain parenchyma and that these nascent
blood vessels are functional. This is a novel finding that gives support for one of the two
competing hypothesis in the field of BBB development. This result was possible with the
advantages of our zebrafish model organism. Furthermore, using a combination of
genetic and chemical approaches, we demonstrate that angiogenesis and barriergenesis,
while occurring simultaneously, use different signaling mechanisms. We demonstrated
that complete inhibition of canonical Wnt signaling blocks CNS angiogenesis, and that
partial inhibition of Wnt signaling permits CNS angiogenesis but prohibits barriergenesis.
We expected Wnt signaling modulation to have an effect on mCherry expression
since it has been shown that Glut1 expression is downstream of Wnt signaling.31,36,64
Additionally, we show that VEGFR antagonists block CNS angiogenesis, but do not
prevent the induction of barrier properties in established blood vessels, indicating that
barriergenesis is independent of VEGF signaling. Ultimately, these results show that
CNS angiogenesis and barriergenesis occur simultaneously, but require distinct signals
for proper formation. Our in vivo model provides a valuable tool for dissecting the
complexities of the BBB that may ultimately lead to new treatment options for a variety
of CNS diseases.
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CHAPTER 4.

A FORWARD GENETIC SCREEN TO UNCOVER BLOODBRAIN BARRIER MUTANTS
Introduction

Genetic Screen Strategies
Genetic screening methods have been successful at dissecting signals important
for developmental processes as well as their unknown functions. In molecular biology,
there are two kinds of genetic screens that can be utilized, reverse and forward. In
reverse genetic screens, a gene of interest is targeted to be deleted or knocked down and
the phenotypic effects of this genetic ablation are observed. Common reverse genetic
techniques include antisense oligonucleotide morpholinos, TILLING, retroviral-mediated
mutagenesis, zinc finger nucleases, conditional bipartite systems for knocking out genes
through transgenesis, TALENS, and the CRISPR/Cas9 system53-55. Forward genetics
takes the opposite approach from reverse genetics. In a forward genetic screen, random
point mutations are created in a founder generation, passed on to successive offspring,
and mutations are discovered based on phenotypes that are identified. Forward genetic
screens usually identify recessive mutations in a F3 generation, but haploid animals can
be screened at an F2 generation to expedite screening for mutant phenotypes109,110.
Therefore it is important to note the different starting and end results in these two kinds
of assays. Reverse genetics is useful for screening for phenotypes if there is a gene of
interest to be studied. Forward genetics proves to be a very useful and an unbiased
strategy at identifying previously unknown pathways important for physiological
processes.
Significance of Forward Genetic Screens
The first forward genetic screens were carried out in micro-organisms and helped
identify the importance between genes and enzymes, gene structure, and even the genetic
code53. Non-vertebrates such as the nematode (Caenorhabditis elegans) and fruit fly
(Drosophila melanogaster) have also been used in forward genetics, elucidating loci
involved in programmed cell death and cell polarity111,112. These findings were
extremely significant to the field of biology and this research contributed to Nobel Prize
awards in Medicine and Physiology. Important pathways that are conserved among
various species have been identified in these model organisms, but their simplistic
morphology limits what biological structures can be observed in these screens.
Zebrafish and Forward Genetic Screens
The zebrafish proved to be a useful vertebrate for forward genetics. It is possible
to perform forward genetic assays in murine models, but intrauterine development, cost,
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and limiting size for pup liters make it difficult to study developmental processes in
mammals109. Because forward genetics is a high-throughput screening strategy, the
fecundity of adults and transparent and rapid development of the embryo made zebrafish
a suitable organism for the first genetic screens initiated by Streisinger and colleagues in
the 1980s113,114. These original zebrafish screens utilized gamma-ray irradiation until
chemical mutagens were preferred in subsequent large-scale screens because of their
ability to effectively generate germ-line mutations in a variety of loci48,49. The two first
large-scale genetic screens in zebrafish in Boston and Tübingen identified over 6,000
mutant phenotypes, one third of these mutants being in developmental processes53. Since
then, genes not only involved in embryogenesis but also in vision, cancer, the
cardiovascular system, and brain development have been identified as well50,51,115-117.
Treatment and Breeding Scheme in Zebrafish Forward Genetic Screens
Typical forward genetic screens in zebrafish utilize breeding schemes for
identification of homozygous recessive mutations that are inherited in a Mendelian
manner in F3 diploid embryos (Figure 4-1). With this approach, founder males are
treated with a chemical teratogen to introduce point mutations into their genome. Nethyl-N-nitrosourea (ENU), one of the most common chemical mutagens, is an alkylating
agent that introduces random point mutations at loci throughout an organism118. The
transfer of the ethyl group from ENU onto oxygen or nitrogen causes mis-pairing during
DNA replication and after two rounds, causes a single base pair substitution and
mutation119.
The regimen and concentration of ENU used to treat zebrafish has been
thoroughly studied, looking at survival rate, fertility, and frequency of mutation120,121.
Efficiency of ENU mutagenesis is typically identified by a specific locus test, whereby
ENU treated males are crossed to fish that are heterozygous for a known recessive
mutation and their subsequent progeny are screened for the known mutant phenotype.
Because ENU affects all of the cells in the adult male, only mutations generated in the
pre-meiotic sperm cells passed onto non-mosaic F1 progeny will be identified in further
generations121. After treated founder males recover, they are bred to wild-type females to
produce a F1 generation. The initial genetic screens reported that every F1 individual
possessed a genetic lesion that affected embryonic development.48,49,53 F1 progeny are
then outcrossed to a polymorphic strain for future genetic cloning or in-crossed to other
F1 progeny to create the F2 generation. Crossing F1 progeny together will increase the
number of screened genomes. After F2 families have been generated and raised to
adulthood, pairs within F2 families are mated to identify the non-mosaic, recessive
mutations in F3 offspring based on phenotypic inspection. The chance of finding a
mutation in a particular mutagenized genome is determined by the number of crosses set
up for that family. The probability of successfully finding a mutation in one family is
shown in Equation 4-1 where n is the number of successful matings between pairs of a
given family48.
P = (1-0.75n)
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(Eq. 4-1)

Figure 4-1. Breeding scheme for a zebrafish F3 forward genetic screen
Founder males are treated with ENU and out-crossed to wild-type females. The F1
generation is produced and offspring are heterozygous for germline mutations. In-crosses
in the F1 or outcrossing F1 hets to wild-type fish will create F2 families. 50% of the fish
within a F2 family are heterozygous for mutations from their F1 parents. F2 fish are
crossed to one another to generate F3 progeny. F3 offspring will be screened for recessive
mutations inherited in a Mendelian manner. Therefore, if a F3 clutch carries a recessive
mutation, 25% of that clutch will present a phenotype.
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For example, if each family is mated to one another six times (n = 6), the
probability of finding a mutation in that family will be P = (1-0.756), where P = 0.82 or
82% whereby only 18% of mutations for that family are lost.48 Rates of mutation after
ENU treatment have been identified as 1.7 embryonic lethal mutation per single
mutagenized genome120.
Materials and Methods
ENU Treatment Materials
For each isopack of ENU, a particular amount of solutions were prepared in a
fume hood each week of treatment. The fume hood was covered in spill pads and the
sash was concealed in aluminum foil to maintain a dark environment for the treated fish.
100 ml of 10 mM NaPO4 buffer (pH 6.5), 1 L of ENU treatment water without tricaine (1
mM NaPO4 (pH 6.5) made in fish system water), 3 L 1 mM NaPO4 buffer with tricaine
for every tank of fish to be treated, 1 mL of 10 mM NaPO4 buffer (made in egg water) for
spectrophotometric readings, two cuvettes, 5 L of inactivating solution (containing 20%
Na2S2O3, 1% NaOH), and stock tricaine at 0.4% were prepared every week. Four larger
mating tanks were used for treatment on each set of fish; one tank with an insert and the
three others without. Two luer tip syringes and 50 mL conical tubes were needed for
preparation of the ENU isopack
ENU Preparation and Handling
After the treatment solutions were prepared, a luer tip syringe was used to add 10
mM NaPO4 buffer to the ENU isopack. A second syringe (with tip attached) was used for
pressure buildup in the isopack because of the displaced gas that was produced as the
buffer was added to the container. 60 mL of 10mM NaPO4 buffer was first added
followed by another 25 mL to total 85 mL of 10 mM NaPO4 buffer in an isopack. 20 mL
of air was then carefully removed followed by 20 mL of ENU stock solution. This 20
mL aliquot was placed into a 50 mL conical tube and repeated so that each of the two
conical tubes would have around 40 mL total between the two. ENU was mixed by
pouring the tubes back and forth. To inactive any hazardous ENU spills and for clean-up,
5 L of inactivating solution containing 20% Na2S203 and 1% NaOH was prepared.
ENU Spectrophotometry Readings
Because each isopack of ENU varied between bottles, the final concentration of
ENU was calculated based on its optical density (OD) value with a spectrophotometer.
Based on previously published screens, 3 mM ENU was the desired concentration for
each treatment120. ENU’s molecular weight is 117.11 grams per mole and at a desired
molarity of 3 mM that would constitute 0.351mg/ml of ENU. For 1 mg/ml of ENU, at a
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spectrophotometer reading of 398 nm, the OD is 0.72122. ENU was diluted 1:20 before
being placed in a cuvette for readings on the spectrophotometer. Therefore, the dilution
factor in 1000 ml treatment water to total to 3 mM per ENU isopack was calculated as
shown in Equation 4-2.
[O.D.398 value] X 20 (dilution factor)
[0.72] X [0.351 mg/ml]

(Eq. 4-2)

1000 mL was divided by this dilution factor to decide what volume of ENU stock was
needed to get a desired final concentration of 3 mM ENU.
ENU Treatment Paradigm and Fish Care
ENU treatment was performed on 23 wild-type homozygous Tg(glut1b:mCherry
;fli1a:EGPF) adult males with positive spawning and fertility histories. Eleven males
and twelve males were separated in two initial treatment tanks, respectively, containing
an insert and regular system water. After the OD of the ENU was calculated and 3 mM
ENU in system water was prepared, each set of fish was transferred with their insert into
the 3 mM ENU treatment water. Fish were bathed in this treatment water for 1 hour in a
quiet and dark fume hood. After 1 hour of 3 mM ENU treatment, the insert was carefully
lifted and inserted into a subsequent water tank containing tricaine, a commonly used
anesthetic for zebrafish. Tricaine was added as a means to help calm the fish down after
ENU treatment. Fish were rinsed in this water for another hour in the quiet and dark.
Fish were transferred to subsequent wash tanks for 1 hour at a time for 2 more rinses,
totaling 1 ENU treatment bath and 3 rinses (Figure 4-2). After rinsing, fish remained in
the last rinse tank overnight in the fume hood to help reduce death that may be caused by
immediately transferring them back into system water123.
The fish’s health was checked the following morning and then they were
transferred back to the fish facility in a large tank with fresh tricaine wash water. A
cardboard box was placed over the tank during transport to maintain a dark environment.
Males would be set up for matings on Monday following ENU treatment and then treated
with ENU on Thursday. This would help the fish get accustomed to mating for future
breeding of the F1 generation. ENU treatment was done once weekly over the course of
three weeks.
F1, F2, and F3 Generations
After three weeks of rest, the surviving ENU males, labeled A through I, were
mated to wild-type Tg(glut1b:mCherry ;fli1a:EGPF) females. These offspring were the
F1 generation and labeled with the letter of their original male father and spawn date. 625
fish were produced for the F1 generation, were raised to a reproductive age, and then
were mated to one another initially or wild-type Tg(glut1b:mCherry;fli1a:EGFP) animals
to produce F2 families. F2 families were labeled with a number starting at 001, the letter f
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Figure 4-2. ENU treatment paradigm for male Tg(glut1b:mCherry;fli1a:EGFP)
Founder males were treated with 3 mM ENU once a week, for three weeks total. After
each isopack of ENU was prepared and treatment water was made at 3 mM ENU, fish
were immersed in the ENU solution for 1 hour in a quiet and dark fume hood. After the
treatment incubation, fish were transferred with an insert to subsequent tanks for washing
in a 1 mM NaPO4 solution containing anesthetic. A total of 1 treatment and 3 washes
were performed. After the last rinse, fish remained in the last tank over-night until they
were transferred back to the fish facility.
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of the original F0 male that gave rise to their F1 parents, and their F2 spawn date. Random
matings between F2 pairs generated F3 progeny. F2 pairs that spawned were isolated
while their offspring were screened. These individual pairs were given an additional
number after their F2 family number as to track each pair. For example, the 6th pair from
family 022 was labeled as pair 22.6. F3 progeny were labeled with the same number as
their isolated F2 parents but their plates noted them as F3 and their spawn date. At least
six successful paired matings within a F2 family were performed to optimize the chance
of finding heterozygous pairs for a given mutation in each family.
F3 Progeny Screening
F3 clutches were treated with PTU made in egg water to restrict pigmentation and
make scoring fluorescence easier. The F3 generation was visually inspected under bright
field during early development and assessed for GFP and mCherry expression in the BBB
at 4 dpf. 4dpf was chosen because mCherry expression increases in intensity from 30hpf
onward and is easily visualized by 4 dpf without maternal contribution. mCherry was
also present in the heart of transgenics which helped served as an internal control for
mutations that would affect the folding and expression of just the mCherry protein. 150
µL of tricaine was added to each F3 dish before visual inspection under a Nikon SMZ
1500 stereoscope with a PRIOR Scientific Lumen 200 PRO Fluorescence Illumination
System. Because we performed a forward genetic screen to identify recessive mutations,
one-quarter of the F3 progeny would possess a mutant phenotype based on Mendelian
probability if their F2 parents were heterozygous carriers for the same mutation.
However, not all mutants were found at this ratio as phenotypic penetrance is not always
Mendelian124.
Mutant Imaging
4-5 dpf mutant and wild-type sibling larvae were anesthetized in 0.04% tricaine
made in PTU. After fish were asleep, they were embedded with 1.2 % low-melting point
agarose in a 35 mm glass bottom petri dish (MatTek). Dorsal z-stack confocal images
were acquired in St. Jude Children’s Research Hospital Cell and Tissue Imaging Facility
on the Nikon C1Si microscope. Images were acquired with either a 20 X lens or a 10 X
lens and a 1.5 X zoom added in the Nikon C1Si software. Each slice was 4 µm thick.
Results and Discussion
Fish Survival and ENU Efficacy
Of the 23 original treated males, 9 males survived and were assigned a letter A- I.
This 39% survival rate falls slightly lower than the realm of what is expected with a 3 by
3 mM ENU treatment regimen120. There are many factors that can induce death during
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and after ENU treatment, including environmental disturbance of light and sound during
treatment, fish developing startling responses, an ineffective dose of anesthetic,
hypersensitivity after treatment to noise and vibrations, and removing a dead fish during a
hyper-sensitive period118. Even though we tried to avoid these issues and had a survival
rate lower than 50 %, ENU teratogenicity was effective in subsequent generations.
To check for the potency of ENU treatment, males were mated to wild-type
females and the offspring was observed for phenotypes with mosaic mutation. As seen in
(Figure 4-3), just after one round of 3 mM ENU treatment, a portion of offspring from
treated males developed abnormally and no longer expressed EGFP from the transgenic
background. ENU founder males were also crossed to Casper females to try and perform
a specific locus test for the nacre and roy alleles. nacre mutants do not possess
melanocytes and roy mutants do not possess iridophores125. After multiple rounds of
mating, not enough embryos were spawned after each trial and no nacre or roy larvae
were identified. After a month of recovery from the ENU treatment paradigm, males
were bred to create the F1 generation. Around 625 F1 fish were generated from outcrossing males A-I. 188 F2 families were generated by F1 incrosses and 22 F2 families
were generated from outcrossing a F1 to a wild-type Tg(glut1b:mCherry ;fli1a:EGFP).
Fewer F2 families were generated from outcrossing an F1 to wild-type transgenics as a
means to cover more mutated genomes. From the 210 F2 families generated, 114 families
survived but not all 114 families ended up having at least six pairs to mate or had equal
sex ratios.
BBB Mutants Discovered from Our Forward Genetic Screen
Of the 68 screened families to date, 4 confirmed BBB mutant lines were identified
and observed over the course of their development (Table 4-1). Some features scored in
bright field included edema, necrosis, brain hemorrhage, and death. Mutants were
identified by a change in barriergenesis by Tg(glut1b:mCherry) expression or a change in
CNS angiogenesis development as indicated in Tg(fli1a:EGFP). Because
Tg(glut1b:mCherry) transgenics also have heart expression, heart mCherry in scored
mutants served as an internal control for mutations that affect the overall folding of the
mCherry protein.
Families 040, 044, and 196 consisted of mutants with normal peripheral
angiogenesis but Tg(glut1b:mCherry) expression was absent or ectopic (Figure 4-4B, D,
and F). These families had extreme cases of brain necrosis and a lack of CNS
angiogenesis. Because brain necrosis was observed prior to and during barriergenesis,
this suggests as it has been previously, that signals from the brain milieu are responsible
for development of a healthy BBB32. Family 196 was also unique because mutants were
identified with a reduction in Tg(fli1a:EGFP) (Figure 4-4L ). This suggests that the
mutation may affect vessel development health and delicate vessels may in turn affect
barrier properties.
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Figure 4-3. Effectiveness of 3 mM ENU after the 1st round of ENU treatment
After only one round of 3 mM ENU treatment, a founder male out-crossed to a wild-type
female produced a portion of developmentally abnormal embryos. (A) Brightfield image
of embryo with heart edema (arrow) and bent back (arrow head). (B) Under GFP
fluorescence, no fli1a:EGFP transgenic expression is visible.
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Table 4-1.

Observation of mutant lines over the course of development

Mutant Line

Glut1
expression

BEC
development

Hemorrhage
(dpf)

Necrosis

Edema

Death (dpf)

22.6

Highly reduced

Reduced

No

No

No

-

40.7

Ectopic; few
positive sprouts

Minimal
sprouting

60% mutants;
2 dpf in brain

CNS

Heart

6 dpf

44.3

Highly reduced

None

3 dpf in brain

CNS

Heart and eye

6-7 dpf

196.1

Reduced

Reduced

No

CNS

Heart

5 dpf
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Figure 4-4. CNS angiogenesis mutants identified from the forward genetic screen
Families 040, 044, and 196 harbored mutants with very little to no CNS angiogenesis (H, J, and L) but normal peripheral
angiogenesis. 44.3 and 196.1 mutants had some mCherry expression but it was ectopically expressed (D and F arrows) compared to
their wild-type sibling clutchmates (C and E).
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Family 022 contained mutants with abnormal CNS angiogenesis but also a
reduction in Tg(glut1b:mCherry) expression (Figure 4-5B). It has been shown in mice
that genes important for BBB development affect GLUT1 expression and also CNS
angiogenesis development35,36,126. It was ideal to find mutants that have a reduction in
Tg(glut1b:mCherry) even though they still do not have completely normal CNS
angiogenesis. Mutants like 22.6 further supports that barriergenesis can be affected
separately from CNS angiogenesis even though these processes occur simultaneously.
Conclusion
We performed the first forward genetic screen to identify mutations that affect
BBB development and maturation using our Tg(glut1b:mCherry) reporter line. Survival
of the F1 larvae may have been low due to the mutations that were generated from the F0
males. Dominant lethal mutations in the F1 generation may also eliminate the chance of
finding heterozygotes in the F2 generation. Just like previous screens, we looked for
recessive mutations transmitted to the F3 generation. Even though we were not able to
confirm ENU efficiency with a specific locus test, we were able to show its efficacy after
one round of treatment. To date in this small-scale screen, we identified 4 BBB mutants
consisting of CNS angiogenesis mutants as well as a mutant that had a reduction in Tg
(glut1b:mCherry). These two classes of mutants suggest a genetic signature exists for
BECs versus peripheral vessels as well as signals that affect barrier properties separately
from CNS angiogenesis. Future endeavors include outcrossing mutant founder pairs to
polymorphic strains, further characterization of each line, and cloning these mutants to
identify regulators of CNS angiogenesis and barriergenesis. Ultimately, understanding
the importance of these genes in barriergenesis could provide new therapeutic targets to
modulate the BBB for drug delivery and prevent BBB breakdown in CNS diseases.
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Figure 4-5. Tg(glut1b:mCherry) mutant and control sibling identified from the
forward genetic screen
Family 022 harbored mutants with some degree of CNS angiogenesis (D) but a decrease
in mCherry expression (B) compared to wild-type expression (A).
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CHAPTER 5. CLONING AND CHARACTERIZATION OF THE FIRST
ZEBRAFISH BLOOD-BRAIN BARRIER MUTANT, 22.6
Introduction
Positional Cloning
The surge of zebrafish forward genetic screens in the 1990’s advanced the
identification of mutation induced phenotypes in the developing vertebrate48,49.
Generating genetic maps with polymorphic markers allowed mutations to be identified
through positional cloning 127,128. Positional cloning, also known as bulk segregant
analysis (BSA), utilizes the linkage of polymorphisms to mutant strains to identify the
genomic region carrying the mutated loci that is causative for a mutant phenotype129,130.
BSA therefore requires the outcross of the parental line carrying the genetic mutation to a
polymorphic strain. Subsequently, heterozygous parents from this hybrid generation are
identified and genomic DNA is isolated from individual mutant and wild-type siblings
from in-crossing hybrid heterozygous parents. Different markers along the genome are
analyzed between pools of the wild-type and mutant DNA until a region with fewer
recombination events is uncovered. Because recombination events occur between loci
that are farther apart, lower levels of recombination in mutant DNA pools will occur
where the mutation is linked. A genomic interval that is linked to a mutation will have
low amounts of recombination and co-segregate with the genetic strain where the
mutation was initially introduced. The resolution of the linked interval is dependent on
the number of meiosis analyzed, where 1 centiMorgen is 1 recombination event in every
100 meioses130. Therefore, more meiosis are needed to define a smaller critical interval
where a mutation will be mapped. After cloning a mutant, studies to perform
characterization of the mutated gene, RNA rescue, genetic complementation, and
phenocopy with gene knock down are typically implemented129. Positional cloning has
been successful at identifying mutations responsible in a range of physiology including
iron transport, gastrulation, and pigmentation genes conserved between zebrafish and
humans131-133.
Next Generation Sequencing
BSA has been efficacious at isolating genes mutated in forward genetic screens
but not every mutant in a forward genetic screen can be successfully cloned with this
strategy50,134. Positional cloning is quite time consuming and tedious if linked markers
are not detected in the initial round of mapping. To circumvent these complications, next
generation sequencing (NGS) strategies have increased the ease of cloning mutants
discovered in zebrafish forward genetic screens135-137. As compared to BSA, fewer
mutants are needed for NGS strategies to produce sufficient resolution for mutation
identification130. Pooled DNA from 20 mutants is adequate for NGS techniques as
compared to a pool of 50 larvae that can resolve 1 centiMorgen in BSA130.
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There are various NGS methods, including Whole Genome Sequencing (WGS),
Whole Exome Sequencing (WES), and RNA-seq. Each of these approaches has its own
pros and cons depending on the type of data that can be generated. Even though the
whole genome and its regulatory regions are analyzed in WGS, over 90% of the zebrafish
genome is non-coding and most causative mutations usually occur in altering exons or
splice sites , making WES a very attractive method130. RNA-seq allows the simultaneous
analysis of expression differences but contains bias on the level and degree of tissue
expression at the time RNA is extracted for use130,138. Such methods produce a large
amount of computational data and the appropriate expertise and software is necessary to
complete the analysis. Ultimately, NGS technology provides a new platform for efficient
identification of mutants isolated in screens whereby prior genetic map linkage is not
needed.
Materials and Methods
Identifying the 22.6 Mutant Line
22.6 mutants were identified in our forward genetic screen with Tg(glut1b:
mCherry; fli1a:EGFP) for BBB mutants. In the 6th pair from the 22nd F2 family
generated from ENU treated male A, around one quarter of the F3 clutch had reduced
mCherry expression on 4 dpf compared to siblings. The 22.6 pair was crossed again to
confirm Mendelian transmission of the recessively inherited phenotype that was seen in
the first mating.
Bulk Segregant Analysis
In order to find genetic linkage to a chromosomal locus, 22.6 mutants were outcrossed to the polymorphic Tubingen Longfin (TL) strain. Upon sexual maturation, fish
were in-crossed to find heterozygous carriers of the 22.6 mutant allele. Screening was
performed based on phenotypic observation of the Tg (glut1b: mCherry) transgene just as
it was performed in the forward genetic screen to identify the original 22.6 pair. A total
of 35 individual wild-type or mutant larvae were collected in 100 % methanol. Fish were
then digested in digest buffer with proteinase K and genomic DNA was isolated with 70
% ethanol. Pooled genomic DNA samples were diluted 1:10 in deionized water for a
mapping PCR. Wild-type or mutant genomic DNA was added into an Invitrogen
Accuprime Taq polymerase master mix. Master mix was added to a 384 well stock
primer plate which contained all of the polymorphic marker primer pairs from the
Massachusetts General Hospital (MGH) panel127. Samples were analyzed on a 4%
agarose gel to look for recombinants.
Primers for markers on linkage groups 3, 11, 14, 22, and 23 were ordered from
Invitrogen for follow-up. Markers surrounding these from the MGH panel were selected
from the ZFIN website and were also used for the follow-up PCR on individual wild-type
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siblings and mutant 22.6/TL. PCR master mixes and parameters were the same as with
pooled DNA. Samples were analyzed again on a 4 % agarose gel to look for
recombinants.
Exome Sequencing
Genomic DNA was isolated from 40 wild-type sibling and mutant larvae with the
Qiagen Mag Attract HMW DNA kit. Larvae were generated from five separate pairs
from the original 022 family. Genomic DNA was analyzed for concentration and purity
using a nanodrop spectrometer. This DNA was then submitted to the Hartwell Center at
St. Jude Children’s Research Hospital. Staff performed a double stranded DNA assay
and captured 3 μg of genomic DNA for sequence capture. The type of sequence capture
used was the Agilent SureSelect Target Enrichment (in solution) Illumina Paired-End
capture. The array/library used was the Agilent SureSelect XT Mouse methylseq-post
capture pool.
From the raw sequencing reads, the quality control, mapping and variant calling
were performed using CLC Genomic Workbench v6.5 (CLC Bio, Denmark). In brief,
the reads were trimmed against the sequencing adapters, and only reads with a
sequencing quality greater than 20 and a read length greater than 50 bp were retained.
The filtered reads were then aligned to the zebrafish reference genome sequence (Zv9
assembly, 2010), and the lists of single-nucleotide variants were generated. To identify
the causative mutation responsible for the 22.6 phenotype, Michael Wang in the Hartwell
Center compared the variants with those of wild type for mutant-specific homozygous
mutations that have impact on proteins, including nonsense, missense and essential splice
mutations. Michael identified a total of 44 mutant-specific mutations, two on
chromosome 8 altering the amino acid sequences and one of them introduced premature
stop codon in g-coupled protein receptor 124.
Polymerase Chain Reaction (PCR) and Sequencing of Candidate 22.6 Mutations
Primers were designed flanking the C2941T mutation (forward
GCGGCGTCCCTCTAATCATA, and reverse ATGCCTAAACCGGTAGCTGT).
Genomic DNA from 10 individual wild-type and 10 22.6 mutants was diluted 1:10 for
PCR. PCR was performed with Accuprime Taq polymerase. After PCR, products were
analyzed on a 1% agarose gel before purification. 20 μl of PCR product was purified
with a Qiagen PCR purification kit. Samples were then nanodropped and 40 ng of
purified PCR was submitted for sequencing to St. Jude Children’s Research Hospital
Hartwell Center. An alignment of each individual wild-type or mutant sequence was
performed against the gpr124 cDNA (complementary DNA) reference sequence found on
the Ensembl database (ENSDART00000112331) in the DNASTAR Lasergene 9
MegAlign software. Samples underwent the same processing for the candidate alpha-2B
adrenoceptor (adra2b) with Ensembl sequence ENSDART00000018663 and primers
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flanking the A748G predicted mutation ( forward ATAAAGGTGGTGGCGAGTCA ,
and reverse GCCTTTGGTGTTCTTGCAGA ).
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) of gpr124
RT-PCR was performed on cDNA from 0- 5 dpf zebrafish. RNA was extracted
from 10 embryos per tube with 50µl Trizol. Following Trizol extraction, RNA was
recovered with a phenol chloroform spin, isopropanol and glycogen precipitation, and
75% ethanol wash. cDNA was synthesized after the Trizol RNA extraction by using an
Invitrogen SuperScript III First Strand kit. The same primers from sequencing the
candidate 22.6 mutation were used for RT-PCR using the Invitrogen Accuprime Taq
polymerase system and a Biorad C1000 Thermal Cycler.
IHC
22.6 mutant and wild-type sibling larvae were collected at 3 or 4 dpf in a 1.5 mL
tube on ice and fixed in 4 % paraformaldehyde at 4 ° C overnight. The next day, larvae
were rinsed in phosphate buffered saline (PBS) three times for five minutes each on a
nutator and then sunk in 30 % sucrose at 4 ° C overnight. After fish rose to the top at the
sucrose’s meniscus, they were removed and embedded in Optimal Cutting Temperature
(OCT) medium in a plastic embedding mold. 12 μm coronal frozen sections were cut on
a Leica cryostat.
Sections were outlined with a pap pen to prevent the transfer of liquid between
positive and negative control sides. Slides were then initially rinsed once in PBS, and
then three times for five minutes each in PBST (PBS, 0.3% TritonX 100) in a slide
chamber on a belly dancer mixer. After rinsing, 5% goat serum with 1% bovine serum
albumin block was added to sections for 1-3 hours. Blocking and antibody staining was
performed in a humidity chamber made out of a sandwich box with wet paper towels.
Primary antibodies rabbit anti Glut at 1 1:200 (Novus Bio), mouse anti Claudin5 at
1:200(Invitrogen), mouse anti GFP at 1:500(Invitrogen), and rabbit anti-GFP at 1:500
(Invitrogen) were diluted in blocking serum and then added to the bottom half of the
sections and incubated at 4°C overnight. The top part of the slide contained the negative
control sections which were never stained with primary antibody but only secondary
antibody. After incubation in primary antibody, slides were rinsed in PBST for 1 hour.
Secondary antibodies were prepared in blocking serum (goat anti mouse 488, goat anti
rabbit 488, goat anti mouse 555, and goat anti rabbit 555 all at 1:200, Invitrogen) and
added to sections at room temperature for 2 hours. Slides were rinsed for another hour
and then cover-slipped and sealed for imaging.
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Cascade Blue, Rhodamine, and Fluorescein
A minimum of five 22.6/TL mutant and wild-type siblings at 4 dpf were injected
IV (intravenous) with a 3,000 Da tracer called Cascade Blue (Invitrogen) or 10k Da
Rhodamine into the common cardinal vein near the heart. Tracers were allowed to get
into circulation for around an hour post-injection and then representative animals were
imaged. Ten mutant or wild-type larvae from the same 22.6/TL clutches were incubated
per well with 50 µM Fluorescein (Fluka) made in PTU water for 30 minutes at room
temperature in the dark. After incubation, larvae were briefly rinsed twelve times in
clean egg water before embedding and imaging. All microinjections were performed
using a PV820 Pneumatic PicoPump (WPI). Injection volumes were calculated using a
0.01 mm Stage Micrometer (Fisher Scientific).Larvae were anesthetized with 0.04%
tricaine made in PTU water, embedded in 1.2% low-melting point agarose on glass cover
slip petri dishes, and were visualized on the Nikon AZ100 or Nikon C1Si confocal.
Results and Discussion
Identification of the 22.6 Line
Our first BBB mutant was identified from the sixth pair in family 022, originating
from ENU-treated male A. Upon screening at 4 dpf for changes in Tg(glut1b:mCherry)
expression, around a quarter of F3 22.6 larvae had little to no mCherry expression in the
BBB compared to siblings. mCherry heart expression was unaffected, suggesting that
this phenotype was not due to a mutation affecting the reporter gene itself. The mutant
progeny from the original 22.6 pair did have a portion of embryos with brain hemorrhage
on 4 dpf, a phenotype reported in the Gpr124 mouse knockout35. However, when 22.6
was out-crossed to TL and new heterozygous carriers were identified, the brain
hemorrhage phenotype was no longer seen.
Cloning the 22.6 Mutation, gpr124
To try and clone 22.6, we performed BSA on pooled genomic DNA from wildtype and mutant siblings while samples were correspondingly submitted for WES
(Figure 5-1). Both experiments were implemented so two independent methods could
confirm identification of the mutant allele.
We first performed the initial PCR on the full MGH panel. After the gels were
analyzed, another round of PCR was performed with follow-up markers on individual
larvae. Combing both techniques has successfully identified linkage and subsequent
alleles in Xenopus tropicalis mutants134. While this is an ideal strategy, positional
cloning is not always guaranteed to work for every mutant. For example, del Viso et al.
(2012) were able to perform this dual approach on the ruby mutant but not on the grinch
mutant134. We were also unsuccessful at identifying a map position with BSA. However,
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Figure 5-1. Workflow comparison of bulk segregant analysis and exome
sequencing for cloning zebrafish mutants from a forward genetic screen
To clone mutants in our forward genetic screen, we wanted to utilize both bulk segregant
analysis and exome sequencing. (A) For genetic mapping, larvae must be out-crossed to
a polymorphic strain to identify linkage in the background which carried the mutation.
For genetic mapping, we analyzed pools of wild-type and mutant genomic DNA with the
MGH mapping panel. We then identified markers with possible linkage and obtained
more primers surrounding those markers for a subsequent PCR. (B) We simultaneously
submitted wild-type and mutant genomic DNA to the Hartwell Center at St. Jude
Children’s Research Hospital for exome sequencing. Hartwell Center scientists used the
Agilent SureSelect Target Enrichment Illumina Paired-End capture and further analysis
was done with the CLC Genomic Workbench v6.5 and zebrafish reference genome
sequence (Zv9 assembly, 2010) to identify a candidate mutation.
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exome sequencing identified a guanine to adenosine point mutation at 39,116,104 bp on
zebrafish linkage group 8 in the gpr124 locus (Table 5-1). At the mRNA level, this
causes a change from cysteine to thymidine at 2941 bp. Because the transcript is in the
reverse orientation, this C2941T mutation causes a premature stop codon in the protein.
adra2b was also identified as a possible hit, but the point mutation in gpr124 seemed
worth following up on first since the base pair changed caused a premature stop in the
protein and gpr124 has been implicated in BBB development (Table 5-1)34,35.
After identification of the point mutation, primers were designed flanking the
C2941T mutation as well as the other candidate A748G mutation. Genomic DNA from
the original fish used for exome sequencing was individually amplified with the flanking
primers, the PCR products were purified, and the samples were then sent off for
sequencing. Each individual wild-type larvae had a cysteine at position 2941in gpr124
cDNA however in each of the mutants, there was a thymidine at 2941 as seen from a
subset of the alignments (Figure 5-2A). Furthermore, the A748G candidate in adra2b
turned out to be a polymorphism, as a subset of wild-type siblings possessed a guanine at
position 748 like the mutant samples (Figure 5-2B).
Characterization of gpr124-/- Mutants
IHC with BBB Markers. The BBB is commonly characterized for its physical,
chemical, and functional properties. To assess these in the 22.6 mutant line, IHC and
tracer injections were performed. Other groups have shown effects on tight junctions and
transporters in BBB mutants35,36,102. Specifically, Cullen et al. (2011) showed that
GLUT1 expression is disrupted in Gpr124-/- mutant mice which agrees with the 22.6
mutant model from our BBB screen35. We knew that the mutation in gpr124 was
predicted to cause a premature stop codon in the protein, but we wanted to know if the
Glut1 protein was affected. To assess if Glut1 protein was affected in mutant BECs, IHC
was performed on transverse sections from larval 22.6/TL mutants. As seen in sections
from wild-type and mutants, the expression level of Glut1 protein was not different
(Figure 5-3A). We also wanted to see if tight junctions were mis-expressed since
hemorrhage was originally seen in 22.6 but not in 22.6/TL mutants. To do this, we
performed IHC with a monoclonal Claudin5 antibody on transverse sections from larval
22.6/TL mutants.
Table 5-1.

Candidate mutations for the 22.6 line

Gene
Chromosome Position Reference Mutation mRNA
Protein
name
gpr124 chr8
39116104 G
A
2941C>T p.Gln981*
adra2b chr8

42259829 T

C
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748A>G

p.Thr250Ala

Figure 5-2. Sequencing larvae for the 22.6 candidate gene mutations
(A) Primers flanking the C2941T mutation were used to amplify genomic DNA from
individual larvae that were used for exome sequencing. A 1200 bp product was
amplified from both wild-type and mutant samples. After PCR products were purified,
they were sent off for sequencing with the same primers used in the PCR amplification.
Sample sequences were aligned to a gpr124 cDNA reference sequence. Alignments
revealed that, as predicted, the wild-type samples possessed a C at position 2941 while
each of the mutants possessed a T. (B) Similarly, PCR was performed with primers
flanking the predicted A748G adra2b mutation. The 971 bp PCR product was sent off
for sequencing with the same PCR primers. As confirmation that gpr124 was mutated
and not adra2b in our 22.6 line, alignment against adra2b cDNA revealed that the
A748G base change was a polymorphism. While all mutant samples contained a G at
position 748, some wild-type samples contained a G at position 748 as well.
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Figure 5-3. Immunohistochemical analysis of BBB markers Glut1 and Claudin5
in 22.6 mutants and wild-type siblings
Antibody staining for Glut1(A) and Claudin5(B) proteins was performed to identify any
differences between 22.6 mutant and wild-type sibling BBB protein marker expression.
Staining revealed that at the protein level, there was no difference in the intensity of
Glut1 or Claudin5 expression even though there are fewer BECs in the mutants as seen
with GFP staining.
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Just as with the Glut1 protein, we did not see any difference at the protein level with the
Claudin5 antibody in 22.6 mutants (Figure 5-3B). The expression of Claudin5 may not
have been affected due to compensation from other tight junction proteins. Also,
Claudin5-/- mice do not experience brain hemorrhage but a “size-selective” leakiness
when injected with tracers suggesting lack of Claudin5 does not cause brain hemorrhages
but a selective opening of the barrier22. Furthermore, signaling pathways important for
barriergenesis, like Wnt signaling, affect Claudin5 expression but not Occludin or ZO-1
demonstrating distinct target genes among proteins that have similar functions in the
barrier36,102.
Functional Studies with Tracers. We no longer saw brain hemorrhages in the
outcrossed 22.6/TL line but still wanted to see if mutant vessels were leakier than wildtype since Gpr124 -/- mice have brain hemorrhages35. To assess the function of the BBB
in 22.6/TL mutants, fluorescent tracers were injected into circulation or bathed on
22.6/TL mutants and wild-type siblings. After IV injection, Cascade Blue, a 3,000 Da
tracer leaked into the mutant brain greater than in wild-type larvae (Figure 5-4). We then
wanted to see if this leakiness would still hold true with a tracer smaller and larger than
Cascade Blue. The BBB of 22.6/TL also showed leakage with 10 kDa Rhodamine and
332 Da Fluorescein tracers (Figure 5-5). While the 22.6/TL mutants did not have
hemorrhages, we still saw leakage with tracers smaller than large plasma proteins like the
78 kDa Vitamin-D binding protein which is a member of the zebrafish albumin family62.
Interestingly, while Rhodamine gets into the brain parenchyma of 22.6/TL, it appears as
if the blood-CSF barrier is still intact (Figure 5-5A arrows).
Conclusion
The 22.6 mutant line was the first mutant identified from our BBB forward
genetic screen. To clone this line, we simultaneously performed BSA and NGS
experiments. Like other groups, we did not get a successful map position with BSA but
were able to clone 22.6 with WES134. WES revealed a point mutation in the gpr124
allele which in turn was predicted to cause a premature stop codon in the protein
sequence. Gpr124 has already been shown to be important for BBB development in
mammals and therefore cloning this mutant validates the authenticity of our screen to
find BBB mutants34,35,126. In order to investigate the structure of the 22.6 BBB, we
looked at Claudin5 expression in mutant BECs. We did not notice a change in protein
levels for Claudin5 in mutants compared to wild-type siblings. We also observed a sizeselective leakiness in mutants with a 3000 Da Cascade Blue but not a 10 kDa Rhodamine
tracer. While the protein level of Glut1did not dramatically decrease in sections, it is
hard to quantify expression level from sections. Also, Tg(glut1b:mCherry) was not
completely absent in the 22.6 line as seen by confocal microscopy. Ultimately, cloning a
gpr124 zebrafish mutant will provide the BBB community with another tool to study
barriergenesis. Furthermore, g-coupled protein receptors are highly targeted in drug
discovery and finding the gpr124 ligand may now be easier with this zebrafish mutant
and model139
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Figure 5-4. 22.6/TL mutants appear “leaky” after IV injections with Cascade
Blue
4 dpf Wild-type and 22.6 mutant siblings were injected with Cascade Blue, a 3,000 Da
tracer into the common cardinal vein. After tracers were in circulation for 1 hour, larvae
were imaged on the Nikon AZ100. As compared to wild-type (D), two representative
mutants had increased fluorescence in the blue channel (I, N). This “leakier” 22.6
phenotype may be attributed to the fact that there are less vessels in the mutant (H, M)
compared to wild-type siblings (C) as captured with GFP.
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Figure 5-5. The 22.6/TL mutant blood-brain barrier is leaky with various sized
tracers
4 dpf wild-type siblings and 22.6/TL mutants were either injected with 1 nl 10 kDa
Rhodamine (A) or bathed for 30 minutes in 50 µM Fluorescein (B). Confocal imaging
revealed that mutants have more leakage of each tracer into the brain (A arrowhead; B
arrow). Even though Rhodamine gets into the brain parenchyma of 22.6/TL, it appears
as if the blood-CSF barrier is still intact (A arrows).
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CHAPTER 6.

A CHEMICAL SCREEN TO IDENTIFY MODULATORS OF
BLOOD- BRAIN BARRIER DEVELPOMENT
Introduction

Importance and Classification of Chemical Screens
The development of new therapeutics has large cost and time implications in the
management of health issues. It is estimated that developing a new drug takes 12-15
years with over $1 billion in costs140. It is also important to sufficiently validate targets
during lead drug discovery as this is one reason why drugs fail to work in the clinic140.
With an advanced understanding in disease etiology and possibilities for therapeutic
targets, small molecule discovery is an extremely prevalent avenue for the development
of new drugs. Small molecule screens, which are more cost-effective and faster assays,
haven been known to make a big impact on drug discovery such as in the field of cancer
biology141.
While it is imperative to advance the field of medicine with new compounds
because of issues like antibiotic and chemotherapeutic resistance, small molecule screens
may effectively repurpose drugs. This type of approach referred to as a “connection
screen” takes well-characterized drugs and identifies compounds that regulate a
biological process of interest 142. Other kinds of screens include targeted, phenotypic,
disease modifier, and library annotation.142,143 Targeted screens utilize genetic reporters
and readout such as fluorescence is monitored. Secondary assays and follow-up with
dose response curves are essential in showing the effectiveness of a chemical hit from a
targeted screen143. Phenotypic screens are assays without any previous knowledge of the
target, but many unrelated biological factors can go into affecting the phenotype143. One
of the drawbacks in a phenotypic screen is the lack of known mechanism. Because
compounds may not be extremely selective, a phenotype may not be caused by a small
molecule binding to a suggested target143. However, many drugs have been successfully
developed by phenotypic screens57. As a kind of genetic model, disease models may be
created in order to find small molecules that target a pathway of interest. Disease
modifier screens test small molecule libraries in order to try and rescue or reduce the
progression of particular disease phenotypes. Lastly, library annotation screens take
novel compounds and characterize them based on the phenotype that is produced in the
screen assay. These screens help characterize newly synthesized compounds that may be
very functionally diverse142. Regardless of the kind of screen, each of these can be
performed in the zebrafish model depending on the hypothesis that needs to be tested.
Chemical Screens in Zebrafish
Zebrafish are an ideal organism for small molecule screens as they are a costeffective model, develop rapidly outside of the mother, are translucent in early
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development, high clutch numbers can be timed when generated, and are small enough to
be used in a high- content and throughput fashion. If later stages are to be analyzed,
pigmentation can also be prevented by treating with the chemical PTU142. Individual
embryos can be placed in 96 and even 384 well plates and the embryos will still develop
normally over time (Figure 6-1). Embryos and larvae can be staged prior to the
developmental window that is desired for testing. Zebrafish can then be delivered to
wells, embryo water may be carefully removed, and the desirable amount of drugging
water can be added back or fish may be delivered to plates in a pre-designated volume.
Drugs can then be added to the zebrafish after the pre-designated volume of water is
added so as to result in a particular final concentration of drug. Depending on the stage
that is to be screened, zebrafish incubate in the compounds for a period of time until they
are phenotypically observed.
Small molecule screens can also supplement genetic screens which are commonly
performed in zebrafish. Hits may modulate paralogs in the zebrafish genome that
resulted from the genome duplication46,142. Transgenesis is also a common technique
applied to the zebrafish which can easily be used in targeted screens. For example, the
commonly used vascular reporter, Tg(fli1a:EGFP) was used in a small molecule screen to
identify compounds that effect development of the vertebrate retina144. Cells extracted
from transgenic zebrafish may also be cultured in vitro and used to screen a higher
volume of compounds145. However, the advantage of using the zebrafish is that behavior
and physiological development of a vertebrate can be monitored versus the fewer and
broader phenotypes assayed in in vitro systems. Absorption, distribution, metabolism,
and excretion studies have not been established in zebrafish yet, but hydrophobicity as
measured by logP values can predict bioavailability in zebrafish treated with compounds
with various molecular weights146. Zebrafish have been a successful model to repurpose
drugs and studies have validated zebrafish small molecule screen hits in mice as well147.
Materials and Methods
Chemical Libraries Tested
Because of its availability in our department and clinical significance, the Food
and Drug Administration (FDA) library was the first library we tested. Subsequent
screens were done with the ENZO Wnt, Autophagy, and Neurotransmitter libraries. The
ENZO libraries were tested with the help of Dr. Steven Finckbeiner.
Staging, Dosing, and Screening Strategy
For the FDA library screen, zebrafish matings were set-up between Tg
(glut1b:mCherry; fli1a:EGFP) males and TL females two days prior to drugging.
Matings were timed so that embryos could be staged the next day. After the plates were
void of unfertilized embryos, embryos were rinsed into a 1% Dimethyl sulfoxide
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Figure 6-1. Zebrafish embryos are amenable for high-content small molecule
screening
Multiple zebrafish embryos can be staged and easily placed into 96-well plates for
chemical screens.
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(DMSO) solution. Three embryos per well were plated in the 1% DMSO water onto a
Perkin Elmer Cell Carrier black plate under the aid of a Nikon SMZ 1500 stereoscope.
On drugging day, wells were checked for unfertilized eggs , water was removed, and 90
µL of 1% DMSO, PTU egg water was added to the wells. We used PTU water to prevent
pigmentation in the animals and make fluorescence screening at 3 dpf easier. An initial
screening dose of 10 µM was used in the FDA screen as that is a reasonable
concentration in zebrafish small molecule screens142. 10 µL of compound was
transferred with a multichannel pipette from a 384 well drug library plate to the 90 µL in
the 96 well plate containing the 24 hpf zebrafish embryos. This produced a 1:100
dilution from a 100 µM stock plate, resulting in the final dosing concentration of 10 µM.
Column 1 was always a negative control, containing fish in 1% DMSO water only.
Column 7 was always a positive control, containing 2 µM Tunicamycin, a drug that we
previously found caused brain hemorrhage and reduced BEC development. After
drugging, plates were placed in a humidity chamber which consisted of moistened paper
towels in a sandwich box. This box containing the drugged embryos was placed in the
28.5°C incubator. The incubator was on a 10 hour light 14 hour dark cycle like the
zebrafish facility. Wells were monitored at 2 dpf under brightfield to look for any
abnormal development such as CNS necrosis or brain hemorrhage. At 3 dpf, embryos
were assessed under brightfield optics as well as mCherry and GFP on a Nikon SMZ
1500 stereoscope with a PRIOR Scientific Lumen 200 PRO Fluorescence Illumination
System. To score for changes in BBB development, embryos were anesthetized with
0.04 % tricaine, around 300 µL of cooled 1.2 % low-melting point agarose was added to
each well, the agarose hardened, and then plates were flipped upside down so that larvae
were now stationary at the bottom of the 96 well plate for screening. Images were also
recorded on the GE InCell 6000 in the High-throughput Screening core in the Chemical
Biology and Therapeutics Department.
For the ENZO library screens, matings were set up like they were for the FDA
screen. At one point, we switched to using Tg(glut1:mCherry) males by Tg(fli1a:EGFP)
females to try and increase clutch size and the number of crosses we could set up. This
time, embryos were cleaned but not plated until drugging at 24 hpf. For plating, embryos
were rinsed from egg water into PTU and then into 1 % DMSO water made in PTU. We
also tried a range of doses for this library consisting of a 100, 10, and 1 µM dose for each
compound plate. 3 embryos were transferred with either 198 or 180 µL 1 % DMSO,
PTU water into the 96 well plates. The range of doses was carried out in a serial dilution
on the Tecan Freedom Evo in the Chemical Biology and Therapeutics Department.
Embryos in plate one had 198 µL of water and 2 µL of stock compound added for a final
concentration of 100 µM. 20 µL from this 100 µM plate was transferred by the Tecan to
plate two with 180 µL to make a 10 µM plate. Another 20 µL from the 10 µM plate was
transferred by the Tecan to the third plate with 180 µL to make the 1 µM plate. Negative
controls were in column 1, consisting of embryos in 1% DMSO, PTU water only.
Positive controls were in column 7 and consisted of 100, 10, or 1 µM DMH4, a potent
angiogenesis inhibitor, or 20, 2, or 0.2 µM Tunicamycin for plates one, two and three,
respectively105. Plates were scored on 2 dpf and 3 dpf just as they were for the FDA
library screen (Figure 6-2).
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Figure 6-2. Weekly workflow for the blood-brain barrier chemical screen
Zebrafish matings were timed between Tg (glut1b:mCherry;fli1a:EGFP) males and TL
females or Tg (glut1b:mCherry) males and Tg(fli1a:EGFP) females. Embryos were
collected and rinsed the next day. On drugging day, embryos were staged at 24 hpf in
black bottom 96 well plates. Compounds were added to the 96 well plates already
containing the zebrafish. At 2 dpf embryos were scored qualitatively for developmental
abnormalities and scored again at 3 dpf for the same abnormalities as well as changes in
reporter gene expression.
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Statin Dose Response Testing
Each of the 10 statins were tested for a dose response on 24 hpf embryos. The
range of doses went from 100 μM down to 100 nM decreasing stepwise in a factor of 3.
The dose responses for all 10 statins were repeated three times. Statins were acquired
from Compound Management in the Chemical Biology and Therapeutics department.
Statin stocks were in 100% DMSO and diluted into 1% DMSO, PTU egg water during
treatment. Zebrafish were monitored for CNS necrosis, brain hemorrhage, and death at
each dose from 24 to 48 hpf.
Tunicamycin, Forskolin, and GBR13069 Treatment
24 hpf Tg (glut1b:mCherry; fli1a: EGFP) embryos were dosed with 1 µM
Tunicamycin, which blocks N-linked glycosylation, 1- 10 µM Forskolin, which elevates
cyclic adenosine monophosphate (cAMP), and 100 – 6.25 µM GBR13069, a dopamine
uptake inhibitor. All compound stocks were in 100 % DMSO and diluted in 1% DMSO,
PTU water for treatment. The GBR13069 dose response was performed by Dr. Steven
Finckbeiner.
Dolichol Kinase (dolk) Morpholino Injections and RT-PCR
1 nl of a 0.5 mM start site morpholino (TAAACATTGTCCACTTCTTGTCCTC)
was injected into the cell of Tg(glut1b:mCherry; fli1a: EGFP) embryos at the single cell
stage. Embryos were monitored over development and scored at 2 dpf for hemorrhages.
All microinjections were performed using a PV820 Pneumatic PicoPump (WPI).
Injection volumes were calculated using a 0.01 mm Stage Micrometer (Fisher Scientific).
RT-PCR was performed on cDNA from 0-5 dpf zebrafish. RNA was extracted
from 10 embryos per tube with 50µl Trizol. Following Trizol extraction, RNA was
recovered with a phenol chloroform spin, isopropanol and glycogen extraction, and 75 %
ethanol wash. cDNA was synthesized after the Trizol RNA extraction by using an
Invitrogen SuperScript III First Strand kit. PCR was performed with dolk (forward,
GTTGAATCTGCGGTGGTGTT and reverse, CAATCCCAAAACCGCAGTCA) and
actin (forward, TGAATCCCAAAGCCAACAGAG and reverse,
TCACACCATCACCAGAGTCC ) primers using the Invitrogen Accuprime Taq
polymerase system and a Biorad C1000 Thermal Cycler.
Microscopy
After treatment or injection, larvae were observed and stage selected for
microscopic documentation. Fish were anesthetized with 0.04 % tricaine and then
embedded dorsal side down in 1.2 % low-melting point agarose in a glass coverslip
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bottom petri dish. Confocal images were acquired together for brightfield, mCherry and
GFP on the Nikon C1Si. Brightfield z-stack images were acquired on the Nikon AZ100.
Results and Discussion
FDA Library Chemical Screen Hit: Statins
From the FDA library, six 384 well plates were tested totaling 884 compounds.
The library was added to 24 hpf Tg(glut1b: mCherry; fli1a: EGFP) embryos to bypass
any effects on initial development but to still target development prior to CNS
angiogenesis at 30 hpf. Our most penetrant hit was a class of compounds known as
statins. Statins are commonly given to patients for lipid lowering therapy to help prevent
coronary heart disease and are well developed inhibitors of the rate-limiting enzyme in
cholesterol biosynthesis, HMG-CoA reductase148. Rosuvastatin, a commonly prescribed
statin, was actually found as an anti-angiogenic inhibitor in another zebrafish chemical
screen, but compounds in that study were added at 20 hpf before intersegmental vessels
formed in the embryo60. Outside of early development, statins are also known to have
beneficial side effects in neurological disorder therapy via pleiotropic effects on
downstream isoprenoid synthesis149.
To our surprise, we found that depending on the statin, embryos developed brain
hemorrhage and/or CNS necrosis at 2 dpf and even death after 24 hours of exposure
(Figure 6-3). Dose responses were repeated three times for each statin and a heat map
was generated to depict the half maximal effective concentration (EC50) for each statin
(Figure 6-4). As depicted in this heat map for a selection of the statins tested, more
lipophilic compounds such as Simvastatin caused severe side effects at lower EC50s
compared to less lipophilic statins like pravastatin. In fact, hemorrhage was seen as high
as 30 μM pravastatin but as low as 100 nM with simvastatin. Pravastatin was not
originally a hit in our FDA screen because the 10 μM dose we used for screening was too
low to cause hemorrhage in the zebrafish. This result is congruent with the BBB
literature, reiterating that lipophilicity is one of the drug qualities that affect BBB
penetration5. Statins also vary at the pharmacokinetic level when it comes to
bioavailability and cytochrome p450 drug metabolism, suggesting another mechanism for
the different effects among this class of drug148.
We then wanted to know if CNS angiogenesis would only be affected if treatment
was performed before or after 24 hpf. Our lab and others have shown that the BBB
develops early in the zebrafish, but we wanted to know if statins still have an effect on
CNS angiogenesis in a zebrafish after the initiation of barriergenesis62. To answer this
question, a time course with 1 µM Atorvastatin and 10 µM Rosuvastatin was performed
as outlined in (Figure 6-5). For treatments done before 4 hpf prior to zygotic
transcription, larvae at 2 dpf had a reduction in CNS angiogenesis (Figure 6-6, top
panel). Interestingly enough as seen with a well-known inhibitor of angiogenesis, statins
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Figure 6-3. Statins induce cerebral hemorrhage and reduce CNS angiogenesis in
the developing zebrafish
Compared to untreated siblings (B), Tg (glut1b:mCherry; fli1a:EGFP) embryos treated at
24 hpf with 1 µM Atorvastatin (G) or 10 µM Rosuvastatin (L) had reduced CNS
angiogenesis. Levels of mCherry expression in statin treated embryos (F, K) were still
similar to control (A). Statin treated embryos also developed cerebral hemorrhages as
seen in dorsal views (I, N arrows) and side views (J, O arrows) unlike their untreated
siblings (D, E).
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Figure 6-4. Zebrafish as a predictive indicator of blood-brain barrier penetration
of statins
Depending on the lipophilicity of the statin, zebrafish developed an array of phenotypes
ranging from brain hemorrhage to death. More lipophilic statins like simvastatin cause
more severe side effects at lower doses versus a less lipophilic statin like pravastatin.
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Figure 6-5. Experimental design for a developmental time course with
Atorvastatin and Rosuvastatin treatments
Tg (glut1b:mCherry; fli1a:EGFP) embryos were treated with 1 µM Atorvastatin or 10
µM Rosuvastatin and then imaged throughout the course of development to see if the
effects of statins still persisted before or after the initiation of barriergenesis.
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Figure 6-6. Statin treatment prior to zygotic transcription disrupts CNS
angiogenesis
Tg (glut1b:mCherry; fli1a:EGFP) embryos were treated with 1 µM Atorvastatin or 10
µM Rosuvastatin before 4 hpf. The top panel shows that by 2 dpf, CNS angiogenesis is
disrupted in statin treated fish (E, H) compared to untreated siblings (B). Interestingly,
the PHBCs of statin treated embryos still undergo barriergenesis as indicated by glut1b
expression (F, I arrows) even though CNS angiogenesis is abnormal. The lower panel
shows that by 3 dpf, larvae have an even more severe reduction in CNS angiogenesis
after incubating in statins for a longer period of time. Treated embryos also seem to
express glut1b ectopically in the brain (D, G).
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delivered less than 4 hpf prevent CNS angiogenesis but still allow glut1b positive PHBC
development to occur (Figure 6-6F and I, top panel arrows). Embryos that incubated in
statins for another 24 h until 3 dpf had a more severe effect on brain vasculature
development and glut1b even seemed to be ectopically expressed (Figure 6-6D and G,
bottom panel) For treatment performed at 24 or 48 hpf until 72 hpf, statins still
disrupted the development of the brain vasculature (Figure 6-7). While CNS
angiogenesis was disrupted when treatment was done after 2 dpf (Figure 6-7E and H,
bottom panel), treatment performed at 24hpf until 72 hpf had a more severe effect on the
development of BECs (Figure 6-7E and H, top panel). Treatment done later from 5 dpf
onward did not produce any brain hemorrhage in the developing larvae.
While a developmental time course of statin treatment had not been performed in
the zebrafish, other groups have previously demonstrated brain hemorrhage induced by
statins during the time we were performing our FDA screen150,151. These groups
suggested hemorrhage was due to inhibition of protein prenylation and absence of
Coenzyme Q10. While these hypotheses were validated, the cholesterol biosynthetic
pathway affects another major downstream biochemical process, N-linked glycosylation.
For our small molecule screens we had been using Tunicamycin, a well-known inhibitor
of N-linked glycosylation, as a positive control. As seen after 1 μM Tunicamycin
treatment at 24 hpf, embryos developed brain hemorrhages and had abnormal CNS
angiogenesis just like statin treated embryos (Figure 6-8). To try and draw a mechanistic
connection between statin-related brain hemorrhage and abnormal vessel development,
we decided to knock down dolk with morpholino technology. Dolk is an enzyme active
at the endoplasmic reticulum, important for N-linked glycosylation, and is upstream of
Tunicamycin’s target. By knocking down dolk, we could investigate whether our
chemical treatment could be phenocopied genetically with morpholinos. While not 100%
penetrant, 1nl of a 0.5 mM dolk start site morpholino injection produced brain
hemorrhage in 10-15% of morphants as well as abnormal CNS angiogenesis
(Figure 6-9B, C). Hemorrhage was also seen at a higher dose of 1nl of 1 mM
morpholino. Morphants also developed a smaller, dented head, curved tails, heart edema,
and had heartbeat without circulation. Because dolk is maternally derived (Figure 6-9A),
this may contribute to the low penetrance of brain hemorrhage especially since the
morpholino becomes more dilute over time. The diffusion of the morpholino may also
explain why the reduction in CNS angiogenesis in dolk morphants was not as severe as
chemical treatment was with Tunicamycin. Similar to statin treatment after 24 hpf, the
dolk morpholino did not disrupt peripheral angiogenesis (Figure 6-10).
ENZO Wnt and Autophagy Library Hit: Forskolin
For the ENZO libraries, we started off with the Wnt and Autophagy compounds.
Wnt is known to be important for barriergenesis as well as a regulator of Glut1
expression, so it was expected to find hits from this library36,102. To our surprise,
Forskolin was a hit common to both the Wnt and Autophagy libraries. Forskolin is a
well-known inhibitor of cAMP production. When dosed at 24 hpf ,10 μM Forskolin
caused abnormal CNS angiogenesis, extreme kinking of the tail, and seizure-like
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Figure 6-7. Statin treatment from 24 or 48 hpf to 72 hpf disrupts CNS
angiogenesis
Tg (glut1b:mCherry; fli1a:EGFP) embryos were treated with 1 µM Atorvastatin or 10
µM Rosuvastatin at 24 or 48 hpf until 72 hpf. The top panel shows that by 3 dpf, CNS
angiogenesis is disrupted in statin treated fish (E, H) compared to untreated siblings (B)
when embryos incubate in compound for 2 days. The lower panel shows that later
treatment at 48 hpf still causes a reduction in CNS angiogenesis (E, H) albeit less severe
than statin treatment at 24hpf for 48 hour exposure.
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Figure 6-8. Tunicamycin causes a similar disruption to CNS vessels as does statin
treatment
Tg (glut1b:mCherry; fli1a:EGFP) embryos were treated with1 μM Tunicamycin at 24
hpf. The next day after treatment, embryos developed hemorrhages in the brain (A,
arrow) and ventricle (A, arrow head) similar to what was seen with statin treatment.
Confocal microscopy revealed that CNS angiogenesis was also disrupted in Tunicamycin
treated embryos (B).
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Figure 6-9. dolk is maternally derived and disrupts CNS angiogenesis when
targeted with morpholinos
RT-PCR was performed for the dolk transcript on 0 – 5 dpf cDNA (A). 1nl of a 0.5 mM
dolk start site morpholino caused 10-15% of morphants to develop brain hemorrhages at
2 dpf (B). Confocal microscopy revealed abnormal CNS angiogenesis in morphants
compared to un-injected siblings (C).
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Figure 6-10. dolk morphants have normal peripheral angiogenesis
Knockdown of dolk in Tg(glut1b:mCherry; fli1a:EGFP) embryos does not affect the
development of peripheral endothelium (E ) compared to the development in un-injected
control siblings (B).
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behavior (Figure 6-11). It is not known whether the spastic behavior of the Forskolin
treated fish was neuro-muscular or seizure-induced but it was a very pronounced
phenotype. A dose response with Forskolin also showed a dose-dependent phenotype for
this compound (Figure 6-11B).
ENZO Neurotransmitter Library Hit: GBR13069
The BBB maintains critical interactions with the cells of the NVU. Groups have
investigated the role of astrocytes and pericytes, but not a lot has been published on the
contribution of neurons to barriergenesis27,33,41. To test the impact of NTs during BBB
development, agonists and antagonists of common NTs were added to developing Tg
(glut1b:mCherry; fli1a:EGFP) embryos at 24 hpf. For this library, we also decided to
test a range of doses, as it has been demonstrated that convulsant agents like
Pentylenetetrazole work in the mM range in zebrafish152. Our most pronounced hit was a
dopamine transporter agonist called GBR13069. In vitro and in vivo experiments with
GBR13069 have validated it as a potent dopamine uptake inhibitor, showing increased
motor availability in naïve mice153. When screening on 3 dpf, we noticed that embryos
treated with 100 µM had a large reduction in mCherry expression. After a subsequent
dose response with GBR13069 and confocal image acquisition, we noticed a reduction in
mCherry expression specifically in the hindbrain of treated embryos (Figure 6-12). This
regional specificity is not surprising as it has been demonstrated that different Wnt
ligands are also expressed regionally and loss of Wnt signaling has a compartmental
effect on the BBB in the forebrain and ventral spinal cord36. Localization of dopamine
receptor in the zebrafish are also expressed in the hindbrain rhombomeres, areas where
the CtAs branch off of the PHBCs108,154.
Conclusion
We performed small molecule screens for chemical modulators of the BBB in our
Tg (glut1b:mCherry; fli1a:EGFP) line with the FDA and select ENZO drug libraries.
With the FDA library we found that our main hit, statins, caused cerebral hemorrhage,
CNS necrosis, and even death when added to embryos at 24 hpf. We saw that when
treated before zygotic transcription, larvae still had abnormal CNS angiogenesis but
PHBCs underwent barriergenesis as indicated by glut1b expression. We have previously
seen a similar result by inhibiting VEGF signaling in BECs, confirming that CNS
angiogenesis and barriergenesis occur via independent mechanisms. When treated with
statins before or after 24 hpf, larvae still had abnormal CNS angiogenesis and brain
hemorrhage.
The severity of the phenotypes correlated to the lipophilicity of each statin,
suggesting that zebrafish can be a predictive model for statin brain penetration. CNS
brain hemorrhage in zebrafish after statin treatment has also been reported by other
groups and helps validate this hit from our independent screen150,151. These groups
suggest the brain hemorrhages were due to a modification in protein prenylation. This
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Figure 6-11. Forskolin was a hit from both ENZO Wnt and Autophagy libraries
10 μM Forskolin treatment at 24 hpf on Tg (glut1b:mCherry; fli1a:EGFP) embryos
caused developmental abnormalities and seizure-like activity by 48 hpf (A). A dose
response with Forskolin from 10 to 1 μM shows a disruption in CNS angiogenesis (B).
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Figure 6-12. GBR13069 dose response shows a decrease in Tg (glut1b:mCherry) in
the hindbrain of the developing zebrafish
GBR13069 affects the hindbrain vasculature when treated at 24 hpf. This effect regresses
with decreasing doses of the compound.
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cellular process modifies many important signaling pathways such as Ras, laminin,
Rho/Rac, and G-proteins and such signaling events have been implicated in BECs155,156.
However, it is important to note that while these other groups suggest mechanisms
through protein prenylation, the cholesterol biosynthesis pathway has other downstream
effects such as N-linked glycosylation. The positive control used in our small molecule
screens, Tunicamycin, is an effective blocker of N-linked glycosylation. Coincidentally
when embryos are treated at 24 hpf with Tunicamycin, they also develop a phenotype
similar to statin treated embryos. After morpholino injections against dolk, an enzyme
involved in N-linked glycosylation upstream of Tunicamycin, we found that there was a
10-15% occurrence of brain hemorrhage in morphants. While brain hemorrhage did not
occur in all of the morphants, carriers of the p21-activated kinase 2a mutation in the
redhead zebrafish mutant also had hemorrhage occurrence less than 100%124. This
demonstrates that phenotypes such as brain hemorrhage may not be 100% penetrant even
with germline mutations. While correlative, this suggests that N-linked glycosylation
could be affected by statins during CNS angiogenesis.
From the ENZO Wnt and Autophagy libraries we screened, we found that
Forskolin was a hit common to both sets of compounds. Enhancing cAMP levels in vitro
enhances tight junctions through TEER and reduced permeability in BECs157. cAMP has
also been shown to elevate the induction of the tight junction Claudin5 in porcine
BECs158. However, processes that affect the initiation of barriergenesis may differ from
signaling as it happens after the barrier is established in adults. For example, Wnt
signaling is important for BBB maturation but is reduced in adults102. In addition to
Forskolin from the ENZO libraries, we found that GBR13069, a dopamine uptake
inhibitor, affects hindbrain CNS angiogenesis in the developing zebrafish. This regional
specificity coincides with transcript expression of dopamine receptors and hindbrain
PHBC development108,154.
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CHAPTER 7.

SUMMARY AND CONCLUSIONS

Among the three CNS barriers, the BBB is crucial for defense against circulating
xenobiotics and endogenous ligands that would otherwise pose a threat to the CNS3. The
BBB is a complex, physiological arrangement of brain endothelium and interacting
astrocytic endfeet, neurons, pericytes, and microglia, all composing the NVU23. Cell
non-autonomous signals between these cells help the BBB adapt its physiological
functions31,33,35,36,40,41. However, the protection the BBB provides the CNS
simultaneously confers drug resistance against therapeutics. These multi-drug resistant
mechanisms hinder the treatment of CNS diseases because efficacious drug volumes
cannot be delivered into the brain5. The paracellular barrier in between brain
endothelium also prohibits the passive diffusion of compounds into the CNS2. On the
contrary, many CNS syndromes such as Multiple Sclerosis, Alzheimer’s and Parkinson’s
disease present alterations in the BBB and consequently augment disease advancement92.
Gaining a better understanding of healthy brain barrier signaling and physiology could
therefore benefit the targeted delivery of CNS therapies and impede the progression of
CNS diseases.
The BBB has been studied for over a century, but only recently have molecular
cues important for barrier development become uncovered31,33,35,40,64. While informative
to the field, these signals have been discovered with a gene candidate approach. Finding
novel genes that regulate the BBB in an unbiased methodology could advance the field of
brain barrier biology.
We hypothesized that zebrafish could be used a model to dissect the molecular
mechanisms important for BBB development, maintenance, and function. We proposed
zebrafish could be used for unbiased chemical and genetic screening assays. To do this,
we initiated two specific scientific aims. The first aim was to design a transgenic BBB
reporter line as no specific BBB reporter lines have been published to date. For the
second aim, we proposed to use our transgenic line for small-scale forward genetic and
small molecule screens to discover molecular modulators of barriergenesis.
Zebrafish are genetically tractable vertebrates and their quick development time
and transparent nature makes them very amenable for developmental studies. Zebrafish
have been widely used for studying different biological processes and have identified
various small molecule hits and genes involved in signaling pathways and physiological
structures57,109,115,146. The ease of mapping zebrafish genetic mutants have also made
zebrafish an attractive model for genetic studies and the recent advancement in
sequencing technology has promoted the appeal of using zebrafish for genetic
screens128,136. Furthermore, zebrafish have recently been used to study brain barriers,
showing they possess a functional and homologous barrier to mammals early in
development61,62,66,76.
To achieve our first aim of creating a BBB transgenic reporter line, we identified
GLUT1 as a major molecular marker for barriergenesis. Rodent BBB studies report
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GLUT1 as a functional indicator of barrier formation and a study simultaneously
performed during the transgenesis of our model confirmed the specificity of Glut1 in the
zebrafish BBB27,28,36,64. To create our BBB transgenic line, we utilized the common
Tol2kit to engineer a DNA construct with a 2.9 kb fragment of the glut1b promoter
upstream of the mCherry transgene84. After engineering our BBB DNA construct, we
micro-injected glut1b:mCherry DNA and Tol2 transposase mRNA into single cell
Tg(fli1a:EGFP) embryos. Observing transient expression, we identified larvae which
expressed glut1b:mCherry specifically in fli1a:EGFP brain endothelium. After
achieving germline transmission of our glut1b:mCherry transgene, we saw expression colocalized only in brain vessels and not in the periphery or circumventricular organs which
lack barrier properties. glut1b expression continued into adulthood and was also
expressed in reproductive tissues.
One of the ultimate goals of creating the first BBB transgenic line was to visualize
the initial stages of barrier development as that had not be done in real time. Two
hypotheses exist, including that nascent CNS vessels are immature and “leaky” during
the first stages of development or that they acquire barrier properties as soon as vessels
migrate into the brain parenchyma1. By performing live confocal microscopy, we were
able to visualize barriergenesis occurring simultaneously with CNS angiogenesis starting
at 30 hpf. This was the first time the initiation of barriergenesis had been demonstrated
in a live vertebrate. With the creation of our Tg(glut1b:mCherry) transgenic line, we
were therefore able to answer one of the paramount questions in brain barrier biology.
We then wanted to characterize our BBB transgenic line to provide additional
evidence that the zebrafish BBB is comparable to mammals as well as tease a part
signaling pathways in a model system amenable to such assays. To assess known
molecular markers of the mammalian BBB in the zebrafish, we performed IHC on Tg
(fli1a:EGFP) sections over the course of zebrafish development. We found that the
transporters Glut1 and Mdr1 as well as the tight junction protein Claudin5 are expressed
as early as 2 dpf and continue their expression into zebrafish adulthood. We already
demonstrated that one of these barrier properties, glut1b, is expressed during initial CNS
angiogenesis, but we wanted to know if these newly formed vessels were also functional.
We performed IV injection of an Albumin tracer conjugated with an Alexa Fluorophore
647. Upon injection and tracer circulation, we were able to visualize that newly formed
brain vessels were impermeable to Albumin. While these results indicate that the
zebrafish BBB is functional and molecularly comparable to mammals, future studies
could examine the histological presence of other markers such as ZO-1, organic anion
transporters, and BCRP, as well as investigate if smaller tracers are more amenable to
leak out of nascent BECs.
Zebrafish provide an excellent model organism for studying developmental
signaling pathways and because of this, we wanted to tease a part Wnt signaling in the
zebrafish BBB as it had been demonstrated to function in the mammalian BBB31,36.
These other Wnt studies used conditional mouse knockouts which were embryonic lethal
and therefore the BBB could not be studied past a particular time point. Even though
various Wnt ligands are expressed in a spatial manner throughout the brain, this is not
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surprising as Wnt signaling is important to development of neural circuitry in
mammals37. To circumvent developmental abnormalities that could affect barriergenesis
before it started, we crossed our BBB transgenic line to an inducible heat shock
transgenic line to express a negative regulator of Wnt signaling, Axin-1. By performing
heat shock after 1 hour, we were able to demonstrate that CNS angiogenesis is ablated
and barrier properties are ectopically expressed as they are in the mammal36. It is
satisfying that we reproduced a result seen in mammals in our BBB line, but without
BECs it is impossible to study barrier properties. To evade this issue, we titrated back the
amount of Axin-1 induction to only 30 minutes of heat shock, and were able to show that
CNS angiogenesis occurred without barriergenesis. This suggests that even though CNS
angiogenesis and barriergenesis occur simultaneously, they do so via different
mechanisms. Therefore, we proposed that barrier properties would not exist without
angiogenesis in the brain as fundamental transplant experiments demonstrated the brain
provides a microenvironment important for barrier function32. To our surprise, after
treating 24 hpf Tg(glut1b:mCherry;fli1a:EGFP) embryos with a potent VEGFR2
antagonist, we saw that CNS angiogenesis did not occur but PHBCs that run alongside
the hindbrain were still glut1b positive. This suggested that angiogenesis is not required
for barrier properties to form and VEGF signaling is not required for barriergenesis.
We performed additional characterization studies with chemical inhibitors of Shh
and BMP signaling as they have been studied in vascular development33,105. After trying
to chemically inhibit Shh with Cyclopamine and BMP with DMH1, we saw no effect on
glut1b expression. While Shh has been implicated in the mammalian BBB, this result
suggests that these signals are not required for glut1b expression in zebrafish BECs.
Genetic knockdown of these pathways could further and more systematically resolve
their contribution to the zebrafish BBB.
The last hypothesis we wanted to examine during the characterization of
Tg(glut1b:mCherry) was the role of shear stress on barrier properties. It has been
demonstrated that the physical circulation of blood and perhaps factors within circulation,
contribute to BBB properties107. Because zebrafish can survive up to a week without a
heartbeat, we decided to perform morpholino knockdown of tnnt2a, a gene responsible
for cardiac contractility in the zebrafish. Upon morpholino injection in our BBB line,
there was no heartbeat but we were surprised to see that the glut1b signal was not
diminished but possibly stronger in tnnt2a morphants. The BEC lumens looked
collapsed compared to un-injected siblings and therefore may explain any increase in
glut1b:mCherry expression that we visualized.
Upon final characterization of our BBB reporter line and completion of the first
specific aim, we utilized the Tg (glut1b:mCherry;fli1a:EGFP) line for a F3 forward
genetic screen and chemical screen. For our genetic screen, adult male
Tg(glut1b:mCherry;fli1a:EGFP)fish were treated with the carcinogenic ENU once a
week for three weeks. Of the original males treated, 9 males survived and were used for
creating the subsequent F1 generation. We were unable to perform a specific locus test
with the nacre and roy loci to calculate an estimated ENU proficiency due to small clutch
size and unwillingness of the F0 males to breed with Casper females. However, after fish
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recovered their first treatment, we tested the efficiency of ENU treatment by crossing
treated males to untreated TL females. We saw that after only one round of treatment,
the ENU concentration was highly effective due to a complete elimination of fli1a:EGFP
expression in progeny from the founder male. We generated 625 F1 males and 210 F2
families. To date, of these 210 families 114 families survived and 68 families have been
screened. From these 68 families, 4 BBB mutants have been identified, confirmed, and
out-crossed to polymorphic strains for genetic studies. In families 40, 44, and 196,
mutants were found that had little to no CNS angiogenesis but normal peripheral
angiogenesis. Family 22 harbored our most interesting mutant, line 22.6, whereby there
was still a degree of CNS angiogenesis that took place but a major reduction in
glut1b:mCherry expression. These 4 lines represent the first zebrafish BBB mutants
produced from a forward genetic screen.
We wanted to follow-up and clone the 22.6 mutant to identify a potential novel
regulator of barriergenesis. Positional cloning is commonly performed in the zebrafish
with bulk segregant analysis PCR129. While this method has cloned zebrafish mutants, it
is not fully guaranteed for every mutant identified in a genetic screen134. To increase our
chances of cloning 22.6, we simultaneously performed exome sequencing on pools from
22.6 mutant and wild-type sibling genomic DNA. After bioinformatics analysis was
performed in the Hartwell Center at St. Jude Children’s Research Hospital, two candidate
mutations were identified. Both candidate alleles were PCR amplified and sequenced
from the original individual wild-type and 22.6 mutant samples. We confirmed that
gpr124 was the mutated allele in the 22.6 line, whereby a G to A point mutation causes a
premature stop codon at 981 amino acids in the protein sequence. The premature stop
codon was also stronger evidence for the mutation of gpr124. Furthermore, sequencing
revealed that the candidate adra2b mutation was a polymorphism among wild-type
siblings. While the first BBB mutant we cloned was in a gene known to be important for
mammalian barriergenesis, this result confirmed our whole screening strategy and that we
could faithfully identify BBB mutants35,126.
We next wanted to characterize the gpr124 -/- mutant to look for similarities and
potential differences between our fish line and the mammalian knockout models.
Gpr124-/- knockout mice present brain hemorrhages and die embryonically35,126. While
we did not identify any brain hemorrhages in gpr124-/- after it was out-crossed to TL, we
did visualize that the gpr124-/- barrier was “leakier” compared to wild-type siblings after
IV injection with 3,000 Da Cascade Blue and 10 kDa Rhodamine tracers. Mutants also
appeared leakier when bathed in 332 Da Fluorescein dye. Because protein albumin is
much larger than these tracers, this could suggest a difference in size-selectivity upon
ablation of gpr124 in zebrafish compared to mammals. We also looked at Claudin5
expression in gpr124-/- to identify if that was the cause for tracer leakage. Claudin5-/mice also do not present brain hemorrhage but do show a size-selective loosening of the
barrier like our gpr124-/ when injected with tracer dyes22. It is hypothesized that the
absence of brain hemorrhage in the zebrafish gpr124-/- may also be due to compensation
from another zebrafish g-coupled protein receptor paralog resulting from the zebrafish
genome duplication event46. Ultimately, identification of the first zebrafish gpr124-/mutant could lead to small molecule screens or future protein studies that identify the
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ligand for this orphan receptor. Identification of the gpr124 ligand could also prove
useful as a therapeutic target in CNS drug delivery as many therapeutics target g-coupled
proteins139. RNA-seq experiments with gpr124-/- and wild-type siblings may elucidate
additional signals important for barriergenesis.
While we spawned the various generations for our F3 forward genetic screen, we
simultaneously performed small molecule screens to identify chemical modulators of the
BBB. To date, we have screened the FDA and ENZO Wnt, Autophagy, and
Neurotransmitter libraries. From the 884 compounds in the FDA library, we identified
our most conspicuous hit to be a class of compounds called statins. We found that
depending on the statin, zebrafish treated at 24 hpf developed CNS necrosis, brain
hemorrhage and even death by 48 hpf and had reduced CNS angiogenesis. Statins are
known reducers of cholesterol biosynthesis, but recent zebrafish studies have shown that
statins induce brain hemorrhage in zebrafish via mechanisms independent of cholesterol
inhibition150,151. While our finding was not unique, our work from the FDA screen was
confirmed by other groups. Furthermore, after performing several dose responses with
the range of statins available, we found that based on the lipophilicity of the statin,
zebrafish were a predictive indicator of BBB statin penetration. With a developmental
treatment time course, we were also able to establish that statin treatment before zygotic
transcription or later at 48 hpf still caused brain hemorrhage and reduced CNS
angiogenesis in the developing zebrafish. Brain hemorrhages were no longer seen in fish
treated at 5dpf, suggesting a developmental effect of statin treatment during
barriergenesis. This raises concern for pregnant women with hypercholesterolemia, but
the safety of statin treatment during pregnancy is dubious due to conflicting evidence and
high treatment regimens in animal studies versus what is observed in humans 159.
Furthermore, signals important for barrier maturation may deviate from signals in
differentiated BECs102.
While mechanisms have been suggested by other groups, we suggested that
modification of N-linked glycosylation could be why statins cause brain hemorrhage.
We suggest this because after treatment with Tunicamycin, a potent inhibitor of N-linked
glycosylation, zebrafish have reduced CNS angiogenesis and develop brain hemorrhages.
Also, upon morpholino knockdown of dolk, the enzyme upstream Tunicamycin’s target,
we find that CNS angiogenesis is disrupted and a percentage of morphants develop brain
hemorrhage. Even though we only saw at most 15% of morphants with brain
hemorrhage, this could be because dolk is maternally derived and the morpholino diffuses
in the animal over time. Future studies using techniques like CRISPR knockout of the
dolk gene may be able to produce a more penetrant brain hemorrhage phenotype and
study the consequence of true dolk knockout effects on the BBB. It would also be
interesting to perform protein or RNA-seq studies on Tunicamycin-treated embryos to
see if there are particular N-linked glycosylated proteins in the BBB that are affected
after Tunicamycin treatment and cause the subsequent brain hemorrhage phenotype.
We identified two other chemical hits from the ENZO library screens, Forskolin
and GBR13069. Forskolin a known elevator of cAMP signaling, has been indicated in
enhancing TEER and reducing tight junction permeability157. Upon treatment with
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Forskolin, zebrafish had increased motor activity and a marked reduction in CNS
angiogenesis. GBR13069 is a dopamine uptake inhibitor which has shown increased
motor activity in mice153. After GBR13069 treatment, zebrafish had a discernible
reduction in the Tg(glut1b:mCherry) signal. This reduction seemed to be hindbrain
specific which is congruent with dopamine receptor expression in the zebrafish larvae154.
Both of these compounds also remained effective with individual dose responses. These
hits confirm the presence of cAMP signaling in the BBB as well as the first report on
how neurons may specifically regulate barriergenesis.
The development of Tg(glut1b:mCherry) helped elucidate questions about
barriergenesis in a developing vertebrate that until now have not been possible. Glut1 is
only one marker for the BBB and therefore it could be suggested that Glut1 cannot be the
solitary indicator of barrier properties. However, this marker is supported by studies
performed in mammals that use Glut1 as a sole indicator of barrier integrity27,35.
Additional zebrafish BBB transgenic lines should be generated to see if the results found
from our studies with glut1b hold true with other markers. We demonstrate that our BBB
line was useful for studying the onset of barriergenesis, pathways that modulate this
process, the discovery of BBB mutants, and identification of compounds that may
uncover novel regulators of barriergenesis. Therefore, the work in this dissertation will
guide the understanding of the molecular mechanisms that help develop and maintain a
healthy BBB. Recognizing these process prove to be crucial for furthering the
development of CNS therapies, targets for better CNS drug penetration, and the
prevention of CNS disease progression.
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